Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 13889. Отображено 100.
16-02-2012 дата публикации

Insecticidal (1,3,5)-triazinyl phenyl hydrazones

Номер: US20120040837A1
Принадлежит: DOW AGROSCIENCES LLC

(1,3,5)-Triazinyl phenyl hydrazones are effective at controlling insects.

Подробнее
03-05-2012 дата публикации

Bait chemistries in hydrogel particles for serum biomarker analysis

Номер: US20120107959A1

This invention describes the identification of novel organic dye chemistries that can be used as affinity baits to capture proteins and other biomolecules useful in the fields of medical diagnostics, environmental science, toxicology, and infectious disease. Incorporation of unique affinity dye compounds within hydrogel capture particles improves analyte yield and preanalytical precision, and stabilizes the analyte against degradation, while increasing measurement sensitivity. The particles in this invention can be used for routine clinical testing as well as for discovery of low abundance disease biomarkers. Example hydrogel particles containing new high affinity bait chemistries were used to identify a new set of human serum biomarkers.

Подробнее
24-05-2012 дата публикации

Materials for organic electroluminescent devices

Номер: US20120126179A1
Принадлежит: Merck Patent GmBH

The present invention relates to 4,4′-substituted spirobifluorenes which are suitable, owing to excellent properties, as functional materials in organic electroluminescent devices. In addition, the present invention relates to a process for the preparation of 4,4′-substituted spirobifluorenes and to the use of these compounds in organic electroluminescent devices.

Подробнее
12-07-2012 дата публикации

Styryl-triazine derivatives and their therapeutical applications

Номер: US20120178758A1
Принадлежит: California Capital Equity LLC

The invention provides Styryl-Triazine derivatives, and further provides methods of using these compounds to modulate protein kinases and to treat protein kinase mediated diseases.

Подробнее
09-08-2012 дата публикации

Substituted 4-aminocyclohexane derivatives

Номер: US20120202810A1
Принадлежит: GRUENENTHAL GmbH

The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.

Подробнее
23-08-2012 дата публикации

Disulfo-type fluorescent whitening agents

Номер: US20120211188A1
Принадлежит: Blankophor GmbH and Co KG

Concentrated aqueous fluorescent whitening agent preparations are disclosed for optically whitening paper, wherein the preparation contains a specific disulfo-type fluorescent whitening agent.

Подробнее
30-08-2012 дата публикации

Enantioselective preparation of quinoline derivatives

Номер: US20120220775A1
Принадлежит: Individual

A process for preparing 8-substituted oxy-5-((R)-2-halo-1-hydroxy-ethyl)-(1H)-quinolin-2-ones or acceptable solvates thereof. The process involves reacting a 5-(α-haloacetyl)-8-substituted oxy-(1H)-quinolin-2-one with a reducing agent in the presence of a chiral agent and a base to form a 8-(substituted oxy)-5-((R)-2-halo-1-hydroxy-ethyl)-(1H)-quinolin-2-one, said chiral agent having a formula I or II wherein M, L, X, R 1 , R 2 and R 3 have the meanings as indicated in the specification.

Подробнее
20-09-2012 дата публикации

Gas Scrubber Having an Integrated Heat Exchanger

Номер: US20120234167A1
Принадлежит: LURGI GMBH

A gas scrubber, equipped with heat exchanger surfaces constructed of thermoplates, suitable for cooling and cleaning a hot gas by avoiding an excessive thermal load of the washing liquid.

Подробнее
01-11-2012 дата публикации

Dyes with changeable solubilities, and methods for their use

Номер: US20120272461A1
Автор: Seth Adrian Miller
Принадлежит: Individual

Solubility changeable dye compositions include a dye component linked via a linker moiety to a stimulus responsive hydrophobic moiety which modulates the solubility of the dye, wherein the hydrophobic moiety is configured to be de-linked from the dye component on exposure to a stimulus and render the dye component more hydrophilic. A method of dying a substrate with such dye compositions includes contacting the dye with the substrate.

Подробнее
08-11-2012 дата публикации

Triazine-aryl-bis-indoles and process for preparation thereof

Номер: US20120283263A1

A novel heterocyclic compound belonging to ‘triazine-aryl-bis-indoles’, useful for the treatment of asthma. The pathway by which this compound inhibits asthma is also demonstrated. The present invention also provides a process for the preparation of above compounds and their derivatives are presented.

Подробнее
13-12-2012 дата публикации

Phenyl-substituted 1,3,5-triazine compound, process for producing the same, and organic electroluminescent device containing the same as component

Номер: US20120313090A1

A phenyl-substituted 1,3,5-triazine compound represented by the general formula (1): wherein Ar 1 and Ar 2 independently represent substituted or unsubstituted phenyl, naphthyl or biphenylyl group; R 1 , R 2 and R 3 independently represent hydrogen atom or methyl group; X 1 and X 2 independently represent substituted or unsubstituted phenylene, naphthylene or pyridylene group; p and q independently represent an integer of 0 to 2; and Ar 3 and Ar 4 independently represent substituted or unsubstituted pyridyl or phenyl group. This compound is suitable for an organic electroluminescent device.

Подробнее
28-03-2013 дата публикации

PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES

Номер: US20130079345A1
Принадлежит:

The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase. 6. The compound according to claim 1 , wherein the compound is selected from the group of compounds consisting of:3-[(4-(2-Methoxyphenyl)-1,3,5-triazin-2-yl)amino]benzenemethanesulfonamide,3-[(4-(4-Fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl)amino]benzenemethane-sulfonamide,3-[(4-(5-Fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl)amino]benzenemethane-sulfonamide,3-[(4-(6-Fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl)amino]benzenemethane-sulfonamide,3-[(4-(3,5-Difluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl)amino]benzenemethane-sulfonamide,3-[(4-(4-Chloro-2-methoxyphenyl)-1,3,5-triazin-2-yl)amino]benzenemethane-sulfonamide,3-[(4-(5-Chloro-2-methoxyphenyl)-1,3,5-triazin-2-yl)amino]benzenemethane-sulfonamide,3-[(4-(2-Methoxy-4-trifluoromethyl-phenyl)-1,3,5-triazin-2-yl)amino]benzene-methanesulfonamide,3-[(4-(2-Methoxy-5-trifluoromethyl-phenyl)-1,3,5-triazin-2-yl)amino]benzene-methanesulfonamide,3-[(4-(5-Hydroxymethyl-2-methoxyphenyl)-1,3,5-triazin-2-yl)amino]benzene-methanesulfonamide,3-[(4-(5-Formyl-2-methoxyphenyl)-1,3,5-triazin-2-yl)amino]benzenemethane-sulfonamide,3-[(4-(2-Ethoxyphenyl)-1,3,5-triazin-2-yl)amino]benzenemethanesulfonamide,3-[(4-(2-Benzyloxyphenyl)-1,3,5-triazin-2-yl)amino]benzenemethanesulfonamide,1-(3-{[4-(2-phenoxyphenyl)-1,3,5-triazin-2-yl]amino}phenyl) ...

Подробнее
11-04-2013 дата публикации

Antimicrobial Compounds and Methods of Making and Using the Same

Номер: US20130090326A1
Принадлежит: Rib-X Pharmaceuticals, Inc.

The present invention relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, and reducing the risk of microbial infections in humans and animals. 3. The compound according to claim 1 , wherein Z is —NRCONR—; or a pharmaceutically acceptable salt claim 1 , ester claim 1 , tautomer claim 1 , or prodrug thereof.5. The compound according claim 1 , wherein (a) a 3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,', '(b) a 3-14 member saturated, unsaturated, or aromatic carbocycle, and', '(c) a single bond,, 'A is selected from'}{'sup': '5', 'wherein (a) or (b) is optionally substituted with one or more Rgroups;'}{'sub': 1-8', '2-8', '2-8, 'claim-text': [{'sub': p', 'p', 'p, 'sup': 6', '6', '6', '6', '6, 'i) 0-4 carbon atoms in any of (a)-(c) immediately above optionally is replaced by a moiety selected from the group consisting of —O—, —S(O)—, —NR—, —(C═O)—, —C(═NR)—, —S(O)NR—, and —NRS(O)NR—,'}, {'sup': '5', 'ii) any of (a)-(c) immediately above optionally is substituted with one or more Rgroups, and'}, {'sub': 1', '8, 'sup': '5', 'iii) any of (a)-(c) immediately above optionally is substituted with —(C-Calkyl)-Rgroups, and'}], 'B is selected from (a) —(Calkyl)-, (b) —(Calkenyl)-, (c) —(Calkynyl)-, (d) a single bond, wherein'}{'sub': 2', '2, 'C is selected from (a) NH, (b) —NHC(═NH)NHand (c) hydrogen;'}or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof.6. The compound according to claim 1 , whereinA is selected from azepanyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, pyridinyl, cyclohexenyl, cyclohexadienyl, dihydropyridyl, furanyl, tetrahydrofuranyl, tetrahydropyridyl, azetidinyl, pyrrolidinyl, piperidinyl, and piperidenyl;{'sup': '5', 'wherein any of A immediately above optionally is substituted with one or more Rgroups;'} ...

Подробнее
18-04-2013 дата публикации

Biguanide Compositions and Methods of Treating Metabolic Disorders

Номер: US20130095140A1
Принадлежит: Elcelyx Therapeutics, Inc.

Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use. 2. A composition according to claim 1 , wherein{'sub': 2', '3', '4', '5', '6', '7, 'R, R, R, R, Rand Rare independently selected from H, methyl, ethyl, propyl or isopropyl; and'}{'sub': '1', 'Ris selected fromH,{'sub': 1', '12', '2, 'Cto Cstraight chain or branched chain alkyl optionally hetero substituted with oxygen, silicon, sulphur or optionally substituted with OH, O-alkyl, SH, S-alkyl, NH, NH-alkyl,'}{'sub': 1', '12', '2, 'Cto Cstraight chain or branched chain alkenyl optionally hetero substituted with oxygen, silicon, sulphur or optionally substituted with OH, O-alkyl, SH, S-alkyl, NH, NH-alkyl,'}{'sub': 1', '12', '2, 'Cto Cstraight chain or branched chain alkynyl optionally hetero substituted with oxygen, silicon, sulphur or optionally substituted with OH, O-alkyl, SH, S-alkyl, NH, NH-alkyl,'}{'sub': 3', '7', '2', '6, 'Cto Ccycloalkyl, Cto Cheterocycloalkyl, where the heterocycle comprises one or two hetero atoms selected from O, S, or N,'}{'sub': 4', '12, 'Cto Calkylcycloalkyl,'}{'sub': 3', '11, 'Cto Calkylheterocycloalkyl, where the heterocycle comprises one or two hetero atoms selected from O, S, or N and wherein N is present in the heterocyclic ring, the nitrogen atom may be in the form of an amide, carbamate or urea,'}phenyl, substituted phenyl, naphthyl, substituted naphthyl,alkylphenyl, alkylsubstituted phenyl, alkylnaphthyl, alkylsubstituted naphthyl,pyridyl, furanyl, thiophenyl, pyrrollyl, oxazolyl, isoxazolyl, thiazolyl, diazolyl, pyrazolyl ...

Подробнее
18-04-2013 дата публикации

Di(arylamino)aryl compound

Номер: US20130096100A1
Принадлежит: Astellas Pharma Inc

The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. As a result of extensive and intensive studies on compounds having an inhibitory effect against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins, the inventors of the present invention have found that the di(arylamino)aryl compound of the present invention has inhibitory activity against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. This finding led to the completion of the present invention. The compound of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive cancer, EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive lung cancer, or EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive non-small cell lung cancer, etc.

Подробнее
25-04-2013 дата публикации

MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES

Номер: US20130099171A1
Принадлежит: Merck Patent GmBH

The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds. 115-. (canceled)19. The compound according to claim 16 , wherein L is a single bond claim 16 , a divalent straight-chain alkylene or alkylidene group having 1 to 10 C atoms claim 16 , or a branched or cyclic alkylene or alkylidene group having 3 to 10 C atoms claim 16 , which is optionally substituted by in each case one or more radicals R claim 16 , where one or more CHgroups claim 16 , is optionally replaced by Si(R) claim 16 , C═O claim 16 , P(═O)R claim 16 , S═O claim 16 , SO claim 16 , —O— claim 16 , —S— or —CONR— and where one or more H atoms is optionally replaced by D or F claim 16 , or a divalent aromatic or heteroaromatic ring system having 5 to 24 aromatic ring atoms claim 16 , which may also be substituted by one or more radicals R claim 16 , or Si(R) claim 16 , C(═O) claim 16 , S(═O) claim 16 , SO claim 16 , P(═O)R claim 16 , O or S.20. The compound according to claim 16 , wherein L is a single bond claim 16 , a divalent straight-chain alkylene or alkylidene group having 1 to 5 C atoms claim 16 , or a branched or cyclic alkylene or alkylidene group having 3 to 6 C atoms claim 16 , which is optionally substituted by in each case one or more radicals R claim 16 , where one or more CHgroups claim 16 , which are not bonded directly to N and are not adjacent claim 16 , is optionally replaced by Si(R) claim 16 , C═O claim 16 , P(═O)R claim 16 , S═O claim 16 , SO claim 16 , —O— claim 16 , —S— or —CONR— and where one or more H atoms is optionally replaced by D or F claim 16 , or a divalent aromatic or heteroaromatic ring system having 5 to 24 aromatic ring atoms claim 16 , which may also be substituted by one or more radicals R claim 16 , or Si(R) claim 16 , C(═O) claim 16 , S(═O) claim 16 , SO claim 16 , P(═O)R claim 16 , O or S.22. The ...

Подробнее
25-04-2013 дата публикации

COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS

Номер: US20130102597A1
Принадлежит: INTERMUNE, INC.

Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system. 3. The method of claim 2 , wherein{'sup': '1', 'Ris selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, cyano, sulfonamido, halo, alkenylenearyl, and heteroaryl;'}{'sup': 2', '2', '1, 'sub': 3', '2', '2', '2', '2', '2, 'Ris selected from the group consisting of aryl; unsubstituted heteroaryl; heteroaryl substituted with one or more substituents selected from halo, unsubstituted alkyl, alkenyl, OCF, NO, CN, NC, OH, alkoxy, haloalkoxy, amino, COH, and COalkyl; haloalkylcarbonyl; cycloalkyl; hydroxylalkyl; sulfonamide; unsubstituted cycloheteroalkyl and cycloheteroalkyl substituted with one to three substituents independently selected from alkyleneOH, C(O)NH, NH, aryl, haloalkyl, halo, and OH; or Rand Rtogether form an optionally substituted 5-membered nitrogen-containing heterocyclic ring;'}{'sup': '4', 'Ris selected from the group consisting of hydrogen, haloalkyl, alkoxy, alkenyl, and alkenylenearyl; and'}{'sup': '5', 'Xis hydrogen.'}4. The method of claim 1 , wherein one of X claim 1 , X claim 1 , and Xis not hydrogen.5. The method of claim 4 , wherein Ris selected from the group consisting of aryl; unsubstituted heteroaryl; heteroaryl substituted with one or more substituents selected from halo claim 4 , unsubstituted alkyl claim 4 , alkenyl claim 4 , OCF claim 4 , NO claim 4 , CN claim 4 , NC claim 4 , OH claim 4 , alkoxy claim 4 , haloalkoxy claim 4 , amino claim 4 , COH ...

Подробнее
02-05-2013 дата публикации

BASIC ZINC CYANURATE FINE PARTICLES, AND METHOD FOR PRODUCING SAME

Номер: US20130108871A1
Принадлежит: NISSAN CHEMICAL INDUSTRIES, LTD.

Basic zinc cyanurate fine particles are produced by subjecting a mixed slurry to wet dispersion using a dispersion medium at a temperature in the range of 5 to 55° C., the mixed slurry being formed by blending water, cyanuric acid, and at least one component selected from zinc oxide and basic zinc carbonate such that the cyanuric acid concentration is 0.1 to 10.0 mass % with respect to water. 1. Basic zinc cyanurate fine particles , having an average particle diameter D , as measured by a laser diffraction method , of from 80 to 900 nm and a specific surface area of from 20 to 100 m/g.2. The basic zinc cyanurate fine particles according to claim 1 , wherein the particles are produced by subjecting a mixed slurry to a wet dispersion with a dispersion medium at a temperature in a range of from 5 to 55° C. claim 1 , wherein the mixed slurry is formed by blending water claim 1 , cyanuric acid claim 1 , and at least one component selected from the group consisting of a zinc oxide and a basic zinc carbonate claim 1 , wherein a cyanuric acid concentration is 0.1 to 10.0 mass % with respect to water.3. A method for producing basic zinc cyanurate fine particles claim 1 , the method comprising subjecting a mixed slurry to a wet dispersion with a dispersion medium at a temperature in a range of from 5 to 55° C. claim 1 , wherein the mixed slurry is formed by blending water and cyanuric acid claim 1 ,wherein a cyanuric acid concentration is 0.1 to 10.0 mass % with respect to water, and further blending at least one component selected from the group consisting of a zinc oxide and a basic zinc carbonate.4. The method according to claim 3 , wherein the basic zinc cyanurate fine particles have an average particle diameter D claim 3 , as measured by a laser diffraction method claim 3 , of from 80 to 900 nm and a specific surface area of from 20 to 100 m/g.5. The method according to claim 3 , wherein the dispersion medium is at least one medium selected from the group consisting of ...

Подробнее
23-05-2013 дата публикации

Carboxamides as inhibitors of voltage-gated sodium channels

Номер: US20130131035A1
Принадлежит: AMGEN INC

The present invention provides compounds that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav 1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Подробнее
23-05-2013 дата публикации

LIGANDS FOR ESTROGEN RELATED RECEPTORS AND METHODS FOR SYNTHESIS OF SAID LIGANDS

Номер: US20130131340A1
Автор: Forman Barry, Yu Donna
Принадлежит:

Estrogen-Related Receptor (ERR) modulating compounds and methods for synthesis of said compounds are described. 2. (canceled)3. The compound of wherein X is S claim 1 , and R is selected from the group consisting of 5-CHand 5-NO claim 1 , and wherein the compound is an estrogen-related receptor (ERR) agonist.4. The compound of wherein X is O claim 1 , and R is selected from the group consisting of 4 claim 1 ,5-CHand 5-CHCH claim 1 , andwherein the compound is an estrogen-related receptor (ERR) agonist.5. (canceled)6. (canceled)7. (canceled)11. The compound of claim 10 , wherein the compound is an ERRα/β/γ agonist.12. The compound of claim 10 , wherein the compound is an ERRβ/γ agonist.13. The compound of wherein the compound is an ERRγ agonist.16. The compound of claim 15 , wherein the compound is an ERRα/β/γ agonist.17. The compound of claim 15 , wherein the compound is an ERRβ/γ agonist.18. The compound of wherein the compound is an ERRγ agonist. This application is a divisional of U.S. patent application Ser. No. 12/475,323, filed May 29, 2009 and now pending, which is a divisional of U.S. patent application Ser. No. 11/336,515, filed Jan. 20, 2006 and issued as U.S. Pat. No. 7,544,838 on Jun. 9, 2009, which claims priority to U.S. Provisional Application No. 60/646,128, filed Jan. 21, 2005, all of which are incorporated herein by reference in their entirety.The present invention relates to ligands and methods for synthesis of said ligands.Metabolic disease, including obesity, diabetes and atherosclerosis, is the leading cause of mortality in industrialized nations. It is estimated that over one-third of the United States population is obese and these individuals are at risk for developing diabetes and atherosclerosis. These disorders are responsible for over 500,000 deaths in the United States each year. The growing incidence of this problem has led to intense interest in identifying new molecular targets and new pharmacologic agents to treat and/or prevent ...

Подробнее
30-05-2013 дата публикации

COMPOUNDS AND COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO

Номер: US20130137634A1
Принадлежит: EMORY UNIVERSITY

The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement. 1. A bone graft composition comprising a 2 ,4-diamino-1 ,3 ,5-triazine derivative or salt thereof.3. The bone graft composition of claim 1 , wherein the 2 claim 1 ,4-diamino-1 claim 1 ,3 claim 1 ,5-triazine derivative is a compound selected from the group consisting of:1-benzyl-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine;1-(4-methoxybenzyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine;1-(3-methoxybenzyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine;1-(4-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine;1-(3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine;1-(3-chloro-4-methoxyphenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine;1-(3-chloro-4-methylphenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine;1-(4-bromo-2-fluorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine;1-(2-bromo-4-methylphenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine;6,6-dimethyl-1-(4-methyl-3-nitrophenyl)-1,6-dihydro-1,3,5-triazine-2,4-diamine;1-(3-chloro-4-fluorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine;1-(3-chloro-5-fluorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine;2-chloro-4-(4,6-diamino-2,2-dimethyl-1,3,5-triazin-1(2H)-yl)phenol;1-(2-chloro-5-methoxyphenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; and1-(2-chloro-4-methylphenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine or salts thereof.4. The bone graft composition of claim 1 , further comprising a growth factor.5. The bone graft composition of claim 4 , wherein the growth factor is a ...

Подробнее
30-05-2013 дата публикации

TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE

Номер: US20130137635A1
Автор: Sands Arthur Thomas
Принадлежит: LEXICON PHARMACEUTICALS, INC.

This invention relates to tryptophan hydroxylase inhibitors, compositions comprising them, and methods of their use for the treatment, management and/or prevention of metastatic bone disease. 2. The use of claim 1 , wherein the metastatic bone disease is osteosclerotic (osteoblastic).3. The use of claim 2 , wherein the metastatic bone disease is bone metastases of prostate cancer.4. The use of claim 3 , wherein the compound is used in combination with a therapeutically or prophylactically effective amount of a second drug.5. The use of claim 4 , wherein the second drug is a luteinizing hormone-releasing hormone agonist (e.g. claim 4 , leuprolide claim 4 , goserelin claim 4 , buserelin); an antiandrogen (e.g. claim 4 , flutamide claim 4 , nilutamide); or an adrenal gland inhibitor (e.g. claim 4 , ketoconazole claim 4 , aminoglutethimide).6. The use of claim 5 , wherein the second drug is mitoxantrone claim 5 , estramustine claim 5 , doxorubicin claim 5 , etoposide claim 5 , vinblastine claim 5 , paclitaxel claim 5 , carboplatin claim 5 , or vinorelbine.11. The pharmaceutical composition of claim 10 , wherein the second drug is mitoxantrone claim 10 , estramustine claim 10 , doxorubicin claim 10 , etoposide claim 10 , vinblastine claim 10 , paclitaxel claim 10 , carboplatin claim 10 , or vinorelbine. This invention relates to tryptophan hydroxylase inhibitors, compositions comprising them, and methods of their use for the treatment, management and/or prevention of metastatic bone disease.The neurotransmitter serotonin [5-hydroxytryptamine (5-HT)] is involved in multiple central nervous facets of mood control and in regulating sleep, anxiety, alcoholism, drug abuse, food intake, and sexual behavior. In peripheral tissues, serotonin is implicated in the regulation of vascular tone, gut motility, primary hemostasis, and cell-mediated immune responses. Walther, D. J., et al., 299:76 (2003). Some evidence also suggests that serotonin can affect bone growth. See, e.g., ...

Подробнее
13-06-2013 дата публикации

Insecticidal Triazines and Pyrimidines

Номер: US20130150365A1
Принадлежит: Vestaron Corporation

The present invention describes novel triazines, their related pyrimidines and their use in controlling insects. This invention also includes new synthetic procedures, intermediates for preparing the compounds, pesticide compositions containing the compounds, and methods of controlling insects using the compounds. 2. A compound of claim 1 , wherein Y is CR.3. A compound of claim 1 , wherein Y is N.4. A compound of wherein halo is Cl or F;{'sup': i', 'j, 'sub': 1', '2, 'Rand Rare H or C-Calkyl; and'}{'sub': 2', '3', '1', '8', '1', '8', '3', '8', '1', '8', '3', '8', '1', '8', '1', '8', '2', '3', '1', '8', '3', '8', '1', '8', '3', '8', '1', '8', '1', '8', '2', '3', '1', '8, 'sup': i', 'j', 'i', 'j, 'Rand Rare independently —H or —C-Calkyl, -aryl, —C-Calkylaryl, —C-Ccycloalkyl, —C-CalkylC-Ccycloalkyl, heterocyclic, —C-Calkylheterocyclic, and —C-CalkylNRR; but when one of Rand Rare -aryl, —C-Calkylaryl, —C-Ccycloalkyl, —C-CalkylC-Ccycloalkyl, heterocyclic, —C-Calkylheterocyclic, and —C-CalkylNRRthen the other of either Ror Ris independently —H or —C-Calkyl.'}5. A compound of wherein{'sub': 2', '3', '1', '6', '1', '6', '6', '6', '1', '6', '6', '6', '1', '6', '6, '1, 2 or 3 of X, Z, and either R, or Ris independently a —C-Ccycloalkyl, —C-CalkylCcycloalkyl, —Caryl, —C-CalkylCaryl or Cheterocyclic or —C-CalkylC-heterocyclic or saturated or unsaturated optionally substituted ring, wherein'}{'sub': 2', '3', '2', '1', '6', '1', '6', '1', '6, 'X, Z, and either R, or Ris optionally independently substituted with 1, 2 or 3, of —H, -halo, —CN, —OH, —OCHCH═CHCl, —C-Calkyl, —O—C-Calkyl, or —S—C-Calkyl;'}{'sub': 1', '6, 'wherein at each occurrence, any —C-Calkyl, is optionally independently substituted with 1-5-halo, —CN or —OH.'}6. A compound of wherein{'sub': 2', '3', '1', '6, '1, 2, or 3 of X, Z, and either R, or Ris independently a heterocyclic or —C-Calkylheterocyclic 6 member saturated or unsaturated optionally substituted ring, wherein'}{'sub': 2', '3', '2', '1', '6', '1', '6', ...

Подробнее
27-06-2013 дата публикации

Use of specific bis(biphenyl)triazine derivatives and mixtures thereof as UV absorbers

Номер: US20130164231A1
Принадлежит: BASF SE

Disclosed is the use of mixtures comprising at least 2 structurally different bis(biphenyl)triazine derivatives of formula (1) wherein X is hydrogen; C-Calkyl which may be uninterrupted or interrupted by one or more oxygen atoms and/or substituted by one or more Rgroups; C-C-cycloalkyl which is substituted by R; —CH((CH)—R)—CO—O—(CH)—R; —CH((CH)—R)—CO—(NR)—(CH)—R; —CO—O—(CH)—R; —CH—CH(—O(CO)—R)—R; —CO—(NR)—(Ch)—R; C-Caryl; allyl; C-Calkenyl which is uninterrupted or is interrupted by one or more oxygen atoms; C-Ccycloalkyl which is uninterrupted or interrupted by one or more oxygen atoms; C-Calkynyl; C-Ccycloalkynyl; Ris hydrogen; unsubstituted or substituted unsubstituted or substituted C-Ccycloalkyl; unsubstituted or substituted C-Caryl; unsubstituted or substituted C-Calkenyl; OR; OH; SR; SOR; SOR; SOH; SOM; or a radical of the formula (c); R, R, R, Rand Rindependently of one another are hydrogen; hydroxyl; —CN; substituted or unsubstituted C-Calkyl; unsubstituted or substituted C-C-cycloalkyl; unsubstituted or substituted C-Calkoxy; unsubstituted or substituted C-Ccycloalkoxy; C-Cphenylalkyl; halogen; halo-C-Calkyl; sulfonyl; carboxyl; acylamino; acyloxy; C-Calkoxycarbonyl; aminocarbonyl; Ris substituted or unsubstituted C-Calkyl; unsubstituted or substituted C-C-cycloalkyl; unsubstituted or substituted C-Caryl; unsubstituted or substituted C-Calkenyl; or C-Cphenylalkyl; M is alkali metal; Rand Rindependently of one another are Rif attached to a carbon atom and are Rif attached to an oxygen atom; p is 0 to 20; m is 0 to 20; Ris hydrogen; hydroxyl; C-Calkyl; C-Ccycloalkyl; C-Calkoxy; C-Ccycloalkoxy; C-C-cycloalkyl or C-Ccycloalkoxy which is interrupted by one or more oxygen atoms; C-Caryl; hetero-C-Caryl; —OR; NHR; R; CONRR; SOH; SOM; OSOH; allyl, C-Calkenyl; C-C-cycloalkenyl which is uninterrupted or interrupted by one or more oxygen atoms; C-C-alkynyl; or C-Ccycloalkynyl; Ris hydrogen; C-Calkyl; C-Ccycloalkyl which is uninterrupted or interrupted by one or more ...

Подробнее
04-07-2013 дата публикации

TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION HAVING AN ANALGESIC ACTIVITY COMPRISING THE SAME

Номер: US20130172317A1
Принадлежит:

The present invention provides novel compounds having a P2Xand/or P2Xreceptor antagonistic effect. 2. The compound according to claim 1 , wherein -L- is —O— claim 1 , or its pharmaceutically acceptable salt or a solvate thereof.3. The compound according to claim 1 , wherein ring B is an aromatic heterocyclic ring claim 1 , or its pharmaceutically acceptable salt or a solvate thereof.4. The compound according to wherein ring B is a thiazole ring claim 1 , an isothiazole ring claim 1 , an oxazole ring claim 1 , an isoxazole ring claim 1 , a pyrazole ring claim 1 , an imidazole ring claim 1 , a triazole ring claim 1 , a furan ring claim 1 , a thiophene ring claim 1 , a thiadiazole ring claim 1 , an oxadiazole ring claim 1 , a pyridine ring claim 1 , a pyrimidine ring claim 1 , a pyrazine ring claim 1 , a pyridazine ring claim 1 , a triazine ring or a benzoxazole ring claim 1 , or its pharmaceutically acceptable salt or a solvate thereof.5. The compound according to claim 1 , wherein ring B is a thiazole ring claim 1 , an isothiazole ring claim 1 , an oxazole ring claim 1 , an isoxazole ring claim 1 , a thiadiazole ring claim 1 , an oxadiazole ring claim 1 , a pyridine ring claim 1 , a pyrimidine ring claim 1 , a pyrazine ring or a pyridazine ring claim 1 , or its pharmaceutically acceptable salt or a solvate thereof.6. The compound according to claim 1 , wherein s′ is an integer of 1 to 2 claim 1 , and at least one of Ris hydroxy claim 1 , carboxy claim 1 , cyano claim 1 , substituted alkyl claim 1 , substituted or unsubstituted carbamoyl claim 1 , substituted or unsubstituted amino claim 1 , substituted or unsubstituted sulfamoyl claim 1 , substituted sulfonyl or substituted sulfinyl claim 1 , or its pharmaceutically acceptable salt or a solvate thereof.7. The compound according to claim 1 , wherein s′ is 1 claim 1 , and R is carboxy or substituted or unsubstituted carbamoyl claim 1 , or its pharmaceutically acceptable salt or a solvate thereof.9. The compound ...

Подробнее
18-07-2013 дата публикации

SULPHUR-CONTAINING TRIAZINE MONOMER THAT CAN BE USED FOR THE SYNTHESIS OF A POLYMER MEMBRANE FOR A FUEL CELL

Номер: US20130184428A1
Автор: Fedurco Milan
Принадлежит:

A sulphur-containing triazine monomer is provided that can be used in the synthesis of a polymer membrane for a PEM-type fuel cell. The sulphur-containing triazine monomer has a structure corresponding to a formula (I): 110-. (canceled)12. The triazine monomer according to claim 11 , wherein Zand Z claim 11 , which are identical or different claim 11 , are selected from a group that includes halogens claim 11 , hydroxyl claim 11 , thiol claim 11 , and combinations thereof.14. The triazine monomer according to claim 12 , wherein Zand Z claim 12 , which are identical or different claim 12 , are halogens.17. The triazine monomer according to claim 11 , wherein the triazine monomer is a suphonated monomer that includes a sulphonic (—SOH) group or a sulphonate (—SOM) group claim 11 , in which M represents an alkali metal cation.18. The triazine monomer according to claim 17 , wherein the sulphonic (—SOH) group or the sulphonate (—SOM) group is carried by a phenyl group or a phenylene group or by at a substituent thereof. The present invention relates to the monomers which can be used for the synthesis of polymers intended in particular, in the sulphonated form, to constitute a solid electrolyte or membrane in a fuel cell.It relates more particularly to the above monomers of the aromatic type comprising a base structural unit with a triazine nucleus.The recent interest in fuel cells arises from their ability to convert chemical energy into electricity with a relatively high yield and a low emission of environmental pollutants. The use of such electrochemical devices extends today from the motor vehicle industry to portable computers, to mobile phones, to the stationary generation of electrical energy and to other applications comprising exploration of the sea and space.It should be remembered first of all that a fuel cell is an electrochemical energy generator in which a chemical reaction between hydrogen and oxygen is maintained under control, which reaction will produce ...

Подробнее
25-07-2013 дата публикации

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Номер: US20130190287A1
Принадлежит: AGIOS PHARMACEUTICALS, INC.

Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein. 2. The compound of claim 1 , wherein Ris independently selected from hydrogen claim 1 , —CH claim 1 , —CHCH claim 1 , —CHOH claim 1 , CN claim 1 , or Rand Rare taken together to form ═O.3. The compound of claim 1 , wherein Rand Rare taken together to form carbocyclyl or heterocyclyl claim 1 , either of which is optionally substituted with up to 3 substituents independently selected from halo. C-Calkyl claim 1 , C-Chaloalkyl claim 1 , C-Calkoxy claim 1 , —CN claim 1 , ═O claim 1 , —OH claim 1 , and —C(O)C-Calkyl.4. The compound of claim 1 , wherein Ris selected from: —(C-Calkyl) optionally substituted with fluoro or —OH; —(C-Calkylene)-O—(C-Calkyl) claim 1 , —(C-Calkylene)-N(R)—(C-Calkyl) claim 1 , —(C-Calkylene)-Q claim 1 , and —O—(C-Calkylene)-Q claim 1 , wherein Q is optionally substituted with up to 3 substituents independently selected from C-Calkyl claim 1 , C-Chaloalkyl claim 1 , C-Calkoxy claim 1 , ═O claim 1 , —C(O)—C-Calkyl claim 1 , —CN claim 1 , and halo.5. The compound of claim 4 , wherein Q is selected from pyridinyl claim 4 , tetrahydrofuranyl claim 4 , cyclobutyl claim 4 , cyclopropyl claim 4 , phenyl claim 4 , pyrazolyl claim 4 , morpholinyl and oxetanyl claim 4 , wherein Q is optionally substituted with up to 2 substituents independently selected from C-Calkyl claim 4 , C-Chaloalkyl claim 4 , ═O claim 4 , fluoro claim 4 , chloro claim 4 , and bromo.6. The compound of claim 1 , wherein Rand Rare taken together to form cyclopropyl claim 1 , cyclobutyl claim 1 , cyclopentyl claim 1 , cyclohexyl claim 1 , tetrahydrofuranyl claim 1 , tetrahydropyranyl claim 1 , oxetanyl claim 1 , bicyclo[2.2.1]heptanyl claim 1 , azetidinyl claim 1 , phenyl and pyridinyl claim 1 , any of which is optionally substituted with up to 2 substituents independently selected from C-Calkyl claim 1 , C-Calkoxy claim 1 , ...

Подробнее
25-07-2013 дата публикации

Surface Modified Nanoparticles

Номер: US20130190493A1
Автор: Imad Naasani
Принадлежит: Nanoco Technologies Ltd

Surface-modified nanoparticles are produced by associating ligand interactive agents with the surface of a nanoparticle. The ligand interactive agents are bound to surface modifying ligands that are tailored to impart particular solubility and/or compatibility properties. The ligand interactive agents are crosslinked via a linking/crosslinking agent, such as hexamethoxymethylmelamine or a derivative thereof. The linking/crosslinking agent may provide a binding site for binding the surface modifying ligands to the ligand interactive agents.

Подробнее
08-08-2013 дата публикации

Formulations for organic electroluminescent devices

Номер: US20130200357A1
Принадлежит: Merck Patent GmBH

The present invention relates to a formulation, in particular for use in organic electroluminescent devices, comprising a carbazole compound, an electron-transport compound, a triplet emitter compound and at least one solvent, where the electron-transport compound encompasses a ketone compound or a triazine compound and where the carbazole compound contains at least two carbazole groups whose N atoms are connected to one another via an aromatic or heteroaromatic ring system. The invention is furthermore directed to organic electro-luminescent devices which comprise the mixtures according to the invention.

Подробнее
08-08-2013 дата публикации

Compounds for the Treatment of Hepatitis C

Номер: US20130203758A1
Принадлежит: BRISTOL-MYERS SQUIBB COMPANY

The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 4. A compound of where Ris trifluoroethyl or a pharmaceutically acceptable salt thereof5. A compound of where Ris benzyl substituted with 0-5 halo claim 1 , alkyl claim 1 , alkenyl claim 1 , haloalkyl claim 1 , alkoxy or haloalkoxy substituents claim 1 , or a pharmaceutically acceptable salt thereof.6. A compound of where Ris (Ar)alkyl or (Ar)cycloalkyl claim 1 , or a pharmaceutically acceptable salt thereof.7. A compound of where Ris hydrogen and Ris hydrogen claim 1 , or a pharmaceutically acceptable salt thereof.8. A compound of where Ris Ar claim 1 , or a pharmaceutically acceptable salt thereof.9. A compound of where Ris Ar claim 1 , or a pharmaceutically acceptable salt thereof.11. A compound of where Aris phenyl para-substituted with 1 CON(R)(R) claim 1 , or a pharmaceutically acceptable salt thereof.13. A composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable carrier.14. A method of treating hepatitis C infection comprising administering a therapeutically effective amount of a compound of to a patient. This application claims the benefit of U.S. Provisional Application Ser. No. 61/595,239 filed Feb. 6, 2012.The disclosure generally relates to the novel compounds of formula I including pharmaceutically acceptable salts, which have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. The disclosure also relates to compositions and methods of using these compounds.Hepatitis C virus (HCV) chronically infects an estimated 170 million people worldwide, with 3 to 4 million infected individuals in the United States alone (Boyer, N. and Marcellin, P. 2000, 32:98-112; Alter, M. J., et ...

Подробнее
26-09-2013 дата публикации

Charge transport layers and films containing the same

Номер: US20130248830A1

The invention provides a film comprising at least two layers, Layer A and Layer B, and wherein Layer(A) is formed from a Composition A comprising at least one compound selected from Formula A: wherein Np is selected from 1-naphthyl or 2-naphthyl, and wherein each R is described herein; and wherein Layer B is formed from a Composition B comprising at least one “HTL compound;” and wherein Layer A is not adjacent to Layer B. The invention also provides a composition comprising at least one compound selected from Formula A: wherein each R is described herein, and wherein the compound has a Tg greater than, or equal to, 115° C.

Подробнее
03-10-2013 дата публикации

Therapeutic methods and agents for treating myotonic dystrophy

Номер: US20130261124A1
Принадлежит: University of Illinois

The invention provides compounds, compositions and methods for treating myotonic dystrophy. The compounds can selectively bind to CUG repeats in RNA, or to CTG repeats in DNA, and inhibit replication of the nucleic acids.

Подробнее
03-10-2013 дата публикации

SEPARATION OF TRIAZINE DERIVATIVES ENANTIOMERS USING TARTARIC ACID

Номер: US20130261300A1
Принадлежит: POXEL

The present invention relates to a new process of separation of triazine derivatives enantiomers involving tartaric acid. 114-. (canceled)16. The process according to claim 15 , wherein at least one of Rand Ris a hydrogen atom.17. The process according to claim 16 , wherein Rand Rare both hydrogen atoms.18. The process according to claim 15 , wherein Rand Rindependently represent C1 to C3 alkyl groups.19. The process according to claim 18 , wherein at least one alkyl group is methyl.20. The process according to claim 15 , wherein the compound of formula (I) is in the form of a salt claim 15 , in particular hydrochloride salt.21. The process according to claim 15 , wherein the triazine derivative of formula (I) is chosen in the group consisting of:2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine,2-amino-6-cyclohexyl-3,6-dihydro-4-dimethylamino-1,3,5-triazine,and a salt thereof.22. The process according to claim 20 , wherein the triazine derivative is 2-amino-3 claim 20 ,6-dihydro-4-dimethylamino-6-methyl-1 claim 20 ,3 claim 20 ,5-triazine hydrochloride.23. The process according to claim 15 , wherein step 1 is performed with a salt of the triazine derivative as starting material.24. The process according to claim 23 , wherein a base is present in the reaction medium.25. The process according to claim 24 , wherein the base is triethylamine.26. The process according to claim 15 , wherein step 1 is performed by the reaction of a triazine derivative of formula (I) with L-(+)-tartaric acid.27. The process according to claim 15 , wherein step 1 is performed in a solvent.28. The process according to claim 27 , wherein the solvent of step 1 is methanol.29. The process according to claim 15 , wherein step 2 is performed by filtration or by centrifugation.30. The process according to claim 15 , wherein step 3 is performed in a solvent.31. The process according to claim 30 , wherein the solvent of step 3 is ethanol.32. The process according to claim 15 , wherein step ...

Подробнее
17-10-2013 дата публикации

Compound for organic light-emitting diode and organic light-emitting diode including the same

Номер: US20130270524A1
Принадлежит: Samsung Display Co Ltd

A compound represented by Formula 1 below may be used in an organic light emitting diode.

Подробнее
07-11-2013 дата публикации

Method for producing pyrophosphate

Номер: US20130294994A1
Принадлежит: Adeka Corp

A producing method of a high-purity pyrophosphate comprising a calcination of the orthophosphate under the condition of 120° C.-350° C.; and a producing method suitable for manufacturing effectively the high-purity melamine pyrophosphate.

Подробнее
07-11-2013 дата публикации

Polymer

Номер: US20130295040A1
Принадлежит: Warwick Effect Polymers Limited

The application provides a method of producing a comb polymer comprising the steps of: (a) Providing: (i) a plurality of monomers which are linear, branched or star-shaped, substituted or non-substituted, and have an olefinically unsaturated moiety, the olefinically unsaturated moiety being capable of undergoing addition polymerisation; (ii) an initiator compound; the initiator compound comprising a homolytically cleavable bond. (iii) a catalyst capable of catalysing the polymerisation of the monomer; and (b) Causing the catalyst to catalyse, in combination with the initiator, the polymerisation of a plurality of the monomers to produce the comb polymer. Catalysts and polymers obtainable by the process are also provided. Preferably, the comb polymer is capable of binding proteins and may be produced from monomers which are alkoxy polyethers, such as poly(alkyleneglycol) or polytetrahydrofuran.

Подробнее
14-11-2013 дата публикации

PREPARATION OF POLYISOCYANATES HAVING ISOCYANURATE GROUPS AND THEIR USE

Номер: US20130303758A1
Принадлежит: BASF SE

The present invention relates to a novel process for preparing polyisocyanates having isocyanurate groups by a partial trimerization of (cyclo)aliphatic diisocyanates in the presence of at least one trimerization catalyst from the group of ammonium salts of lactames and to the use of the thus obtainable polyisocyanates having isocyanurate groups as a polyisocyanate component in polyurethane coatings. 1. A process for preparing isocyanurate-containing polyisocyanates , the process comprising at least partly trimerizing at least one (cyclo)aliphatic diisocyanate in the presence of at least one trimerization catalyst comprising at least one salt comprising a tetrasubstituted ammonium cation and an anion of a lactam.3. The process according to claim 2 , wherein Rto Rare independently selected from the group consisting of methyl claim 2 , ethyl claim 2 , 2-hydroxyethyl claim 2 , 2-hydroxypropyl claim 2 , n-propyl claim 2 , isopropyl claim 2 , n-butyl claim 2 , sec-butyl claim 2 , tert-butyl claim 2 , pentyl claim 2 , hexyl claim 2 , heptyl claim 2 , octyl claim 2 , 2-ethylhexyl claim 2 , nonyl claim 2 , decyl claim 2 , dodecyl claim 2 , phenyl claim 2 , α- or β-naphthyl claim 2 , benzyl claim 2 , cyclopentyl and cyclohexyl.4. The process according to claim 2 , wherein a sum of carbon atoms in the radicals Rto Ris at least 11.5. The process according to claim 2 , wherein Ris selected from the group consisting of methylene claim 2 , 1 claim 2 ,2-ethylene claim 2 , 1 claim 2 ,3-propylene claim 2 , 1 claim 2 ,3-butylene claim 2 , 1 claim 2 ,4-butylene claim 2 , 1 claim 2 ,5-pentylene claim 2 , 1 claim 2 ,5-hexylene claim 2 , 1 claim 2 ,6-hexylene claim 2 , 1 claim 2 ,8-octylene claim 2 , 1 claim 2 ,10-decylene claim 2 , 1 claim 2 ,12-dodecylene claim 2 , 2-oxa-1 claim 2 ,4-butylene claim 2 , 3-oxa-1 claim 2 ,5-pentylene and 3-oxa-1 claim 2 ,5-hexylene.6. The process according to claim 1 , wherein the ammonium cation is selected from the group consisting of tetraoctylammonium ...

Подробнее
14-11-2013 дата публикации

Photochemical crosslinkers for polymer coatings and substrate tie-layer

Номер: US20130303759A1
Принадлежит: Innovative Surface Technologies LLC

The invention describes novel crosslinking compounds that include photoactivatable moieties. Several families of compounds are disclosed that can include one or more hydrophilic moieties that help to solubilize the compounds in aqueous environments.

Подробнее
28-11-2013 дата публикации

Novel carboxylic acid derivatives, their preparation and use

Номер: US20130317044A1
Принадлежит: Abbott GmbH and Co KG

Carboxylic acid derivatives where R—R 6 , X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.

Подробнее
28-11-2013 дата публикации

AFFINITY ADSORBENTS FOR FIBRINOGEN

Номер: US20130317217A1
Принадлежит: PROMETIC BIOSCIENCES LTD

For the separation, removal, isolation, purification, characterisation, identification or quantification of fibrinogen or a protein that is a fibrinogen analogue, an affinity adsorbent is used that is a compound of formula II 3. The compound claim 1 , according to claim 1 , wherein VRRis or includes a cyclic structure.4. The compound claim 1 , according to claim 1 , wherein the cyclic structure is morpholine. This application is a divisional application of co-pending application Ser. No. 11/913,528, filed Aug. 24, 2009; which is a National Stage Application of International Application No. PCT/GB2006/001695, filed May 9, 2006; which claims priority to Great Britain Application No. 0509442.0, filed May 9, 2005; all of which are incorporated herein by reference.This invention relates to compounds and their use as affinity ligands.Fibrinogen is a dimeric protein, each half of which is composed of disulfide-bonded polypeptide chains designated Aα, Bβ and γ. In the liver, the genes for the Aα- and Bβ-chains encode single products of 610 and 461 amino acid residues, respectively. In contrast, alternative splicing of transcripts of the γ-chain gene yield γ-chain variants of slightly different lengths (411 and 427 residues), the shorter of which constitutes ˜90% of the final product. The predominant form of fibrinogen is secreted into the circulation with a molecular mass of ˜340 kDa. Following its secretion from the liver, the protein exists not only in plasma, but also in lymph and interstitial fluid. In healthy individuals, the concentration of fibrinogen in plasma is between 4 and 10 μM. Importantly, that concentration can increase by as much as much as 400% during times of physiological stress.Fibrinogen is converted to fibrin by thrombin, a trypsin-like serine proteinase. Thrombin hydrolyzes at least two specific Arg-Gly bonds within fibrinogen. This process leads initially to the formation of fibrin protofibrils which can associate laterally, forming thicker fibres ...

Подробнее
05-12-2013 дата публикации

Compact Multifunctional Ligand to Enhance Colloidal Stability of Nanoparticles

Номер: US20130323777A1
Принадлежит: US Naval Research Laboratory NRL

A ligand design allows compact nanoparticle materials, such as quantum dots (QDs), with excellent colloidal stability over a wide range of pH and under high salt concentrations. Self-assembled biomolecular conjugates with QDs can be obtained which are stable in biological environments. Energy transfer with these ligands is maximized by minimizing distances between QDs/nanoparticles and donors/acceptors directly attached to the ligands or assembled on their surfaces.

Подробнее
05-12-2013 дата публикации

SYSTEM AND PROCESS FOR MELAMINE PRODUCTION BY GAS-PHASE QUENCHING METHOD OF ENERGY EFFICIENT AND COST SAVING TYPE

Номер: US20130324720A1
Принадлежит:

A system and process for melamine production by gas-phase quenching method and its process are provided. The said system includes a urea scrubber, after which a fluidized bed reactor, a hot-air cooler, a hot-air filter, a crystallizer and a melamine collector are installed in series successively, where the said melamine collector is connected to the said urea scrubber and the said fluidized bed reactor is connected to a carrier gas pre-heater which is connected to a carrier gas compressor; the said system further includes a gas-liquid separator which is connected to the said urea scrubber which is connected to a crystallizer; wherein a cool air blower is provided between the said gas-liquid separator and the crystallizer. The production system of the invention has the advantages of high productivity, stable operation, low energy consumption, low investment and high economic value of tail gas. 1. A system for melamine production by gas-phase quenching method , including:A urea scrubber, after which a fluidized bed reactor, a hot gas cooler, a hot gas filter, a crystallizer and a melamine collector are installed in series successively, where the said melamine collector is connected to the said urea scrubber;The said fluidized bed reactor is connected to a carrier gas pre-heater which is connected to a carrier gas compressor;The said system for melamine production further comprises a gas-liquid separator connected to the said urea scrubber that is connected to the said crystallizer, The said carrier gas compressor is connected to the said gas-liquid separator;wherein a cold gas blower is provided between the said gas-liquid separator and the said crystallizer.2. A system for melamine production according to claim 1 , wherein a cold gas cooler is provided between the said cold gas blower and the said crystallizer.3. A system for melamine production according to claim 1 , wherein the said carrier gas compressor is connected with the said gas-liquid separator via the said ...

Подробнее
19-12-2013 дата публикации

Pentamethylenediisocyanate, method for producing pentamethylenediisocyanate, polyisocyanate composition, polyurethane resin, and polyurea resin

Номер: US20130338330A1
Принадлежит: Mitsui Chemicals Inc

A Pentamethylene diisocyanate is obtained by phosgenating pentamethylenediamine or its salt obtained by a biochemical method, and contains 5 to 400 ppm of a compound represented by the general formula (1) below and a compound represented by the general formula (2) below in total:

Подробнее
26-12-2013 дата публикации

PROCESS OF ISOLATING ENANTIOMER COMPONENTS FROM ENANTIOMER MIXTURES BY PARTICLE-SIZE-CONTROLLED CRYSTALLIZATION

Номер: US20130345421A1
Принадлежит:

The present invention discloses a process for isolating enantiomer components from a mixture of enantiomers through particle-size-controlled crystallization, comprising the steps of: (a) forming a solution of a mixture of enantiomers (R) and (S) in a solvent in the absence of any further additives or agents; (b) seeding the solution of step (a) simultaneously or consecutively with seed crystals of enantiomer (R) and with seed crystals of enantiomer (S), wherein the seed crystals of enantiomer (R) differ in size and/or in quantity from the seed crystals of enantiomer (S) to allow separation of the crystals composed of a mixture enriched with enantiomer (R) from the crystals composed of a mixture enriched with enantiomer (S); (c) inducing simultaneous crystallization of enantiomer (R) and enantiomer (S); and (d) isolating crystals composed of a mixture enriched with enantiomer (R) from crystals composed of a mixture enriched with enantiomer (S) through size separation of the crystals, preferably through sieving, melting or sedimentation, in particular through sieving. 2. The process as claimed in claim 1 , further comprising the steps of:(e) dissolving the isolated crystals composed of a mixture enriched with the enantiomer (R) in a solvent in the absence of any further additives or agents and, separately therefrom, dissolving the isolated crystals composed of a mixture enriched with the enantiomer (S) in a solvent in the absence of any further additives or agents;(f) seeding the solution of enantiomer (R) with seed crystals of enantiomer (R) and, separately therefrom, seeding the solution of enantiomer (S) with seed crystals of enantiomer (S);(g) inducing crystallization of enantiomer (R) and, separately therefrom, inducing crystallization of enantiomer (S);(h) isolating the crystals composed of a mixture further enriched with enantiomer (R) and, separately therefrom, isolating the crystals composed of a mixture further enriched with enantiomer (S).3. The process as ...

Подробнее
02-01-2014 дата публикации

Molecular glasses with functionalizable groups

Номер: US20140005370A1
Автор: Olivier Lebel
Принадлежит: Minister of National Defence of Canada

Disclosed herein is a compound having Formula I: or a salt thereof, in which R 1 , R 2 and R 3 are as defined herein. Also disclosed are processes to prepare compounds of Formula I and use of compounds of Formula I to prepare stable glassy phases.

Подробнее
02-01-2014 дата публикации

Process for the preparation of s-triazine compounds

Номер: US20140005387A1
Автор: Kroner Rudi
Принадлежит: BASF SE

A process is described for the preparation of s-triazine derivatives of the formula in which R is a C-C-alkyl radical, by reacting a cyanuric acid halide with a p-aminobenzoic acid ester, which comprises a C-C-alkyl radical as radical of the ester alcohol, in a molar ratio of 1:3 to 1:5 in a xylene isomer mixture as solvent. 10 The process is characterized in that the solvent is used in amounts of from 0.6 to 2.1 mol/l. 3. The process according to claim 1 , characterized in that the xylene isomer mixture is azeotropically dewatered prior to the start of the reaction.5. The process according to claim 1 , characterized in that the reaction is carried out at a temperature of 85-140° C.6. The process according to claim 1 , characterized in that the p-aminobenzoic acid ester is dosed stoichiometrically.7. The process according to claim 1 , characterized in that the cyanuric acid halide is used as suspension with the azeotropically dewatered xylene isomer mixture.8. The process according to claim 7 , characterized in that cyanuric acid halide adhering to the reaction vessel is removed using rotating cleaning nozzles which are operated with the solvent under pressure.9. The process according to claim 1 , characterized in that the p-aminobenzoic acid ester purified by vacuum distillation is introduced into the reactor which comprises the dewatered xylene isomer mixture and heated to 80-110° C. claim 1 , and then the cyanuric acid halide suspension is metered in at a temperature of 110-120° C. The present invention relates to a process for the technically simple and economic preparation of s-triazine compounds, which can be used as photoprotective agents.DE-A 32 05 398 describes s-triazine derivatives which are substituted by radicals of p-aminobenzoic acid esters, which are extraordinarily good photoprotective agents. According to the preparation examples, the compounds are prepared by reacting cyanuric chloride with a p-aminobenzoic acid ester in relatively large amounts ...

Подробнее
23-01-2014 дата публикации

Method for producing 2-(triazinylcarbonyl) sulfonanilides

Номер: US20140024828A1
Принадлежит: Bayer Intellectual Property GmbH

The present application relates to a process based on the oxidative ring opening of a compound with oxindole structure for preparation of substituted 2-(triazinylcarbonyl)sulfonanilides of the formula (1-1) proceeding from N-sulfonyl-substituted 3-triazinyloxindole of the formula (2-1), and to the 2-(triazinylcarbonyl)sulfonanilides of the formula (1-1) thus prepared, and to the use thereof as intermediates for the synthesis of fine chemicals and of active ingredients in the agricultural sector. 2. The process for preparing a 2-(triazinylcarbonyl)sulfonanilide of formula (1-1) as claimed in claim 1 , where{'sup': 1a', '1d, 'Rto Rare each independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine and from'}{'sub': 1', '6', '1', '4', '3', '7, '(C-C)-alkyl where the alkyl radical is branched or unbranched and is unsubstituted or substituted by at least one substituent selected from the group consisting of fluorine, chlorine, (C-C)-alkoxy or (C-C)-cycloalkyl,'}{'sub': 3', '7', '1', '4', '3', '7', '1', '4, '(C-C)-cycloalkyl where the cycloalkyl radical is unsubstituted or substituted by at least one substituent selected from the group consisting of fluorine, chlorine, (C-C)-alkyl or (C-C)-cycloalkyl or (C-C)-alkoxy,'}{'sub': 1', '6', '1', '4', '3', '7, '(C-C)-alkoxy where the alkoxy radical is branched or unbranched and is unsubstituted or substituted by at least one substituent selected from the group consisting of fluorine, chlorine, (C-C)-alkoxy or (C-C)-cycloalkyl,'}{'sub': 3', '7', '1', '4', '1', '4, 'claim-text': [{'sup': '2', 'sub': 1', '6, 'Ris (C-C)-alkyl where the alkyl radical is fully or partly substituted by fluorine, and'}, {'sup': 4', '5, 'claim-text': {'sub': 1', '6', '1', '4', '3', '7, '(C-C)-alkoxy where the alkoxy radical is branched or unbranched and is unsubstituted or substituted by at least one substituent selected from the group consisting of fluorine, chlorine, (C-C)-alkoxy or (C-C)-cycloalkyl.'}, 'Rand Rare ...

Подробнее
06-02-2014 дата публикации

AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS

Номер: US20140038968A1
Принадлежит:

The present invention relates to certain novel compounds of Formula (I): 2. The compound of wherein Ais phenyl claim 1 , 2 claim 1 ,3-dihydro-benzofuranyl wherein the point of attachment to Lis at the benzo ring claim 1 , or 1-methyl-benzotriazol-5-yl; wherein phenyl is optionally substituted with a substituent selected from the group consisting of Calkyl claim 1 , Calkoxy claim 1 , fluoro claim 1 , chloro claim 1 , and Calkylthio; and wherein phenyl is optionally further substituted with a fluoro or chloro substituent.3. The compound of wherein Ais 4-ethyl-phenyl claim 1 , 3 claim 1 ,4-dichloro-phenyl claim 1 , 4-fluoro-phenyl claim 1 , 4-chloro-phenyl claim 1 , 4-methylthio-phenyl claim 1 , 2 claim 1 ,3-dihydro-benzofuran-5-yl claim 1 , or 1-methyl-benzotriazol-5-yl.4. The compound of wherein Lis (CH)— optionally substituted with a substituent selected from the group consisting of methyl and allyl claim 1 , provided that r is 1 to 3 when Ais other than hydrogen.5. The compound of wherein Lis —CH—.6. The compound of wherein P is —CH—.7. The compound of wherein Ais hydrogen claim 1 , a heteroaryl other than unsubstituted pyridin-2-yl claim 1 , dihydrobenzofuranyl claim 1 , or phenyl optionally substituted at the meta and para positions with one to three substituents independently selected from the group consisting of Calkyl claim 1 , Calkoxy claim 1 , halogen claim 1 , halogenated Calkyl claim 1 , halogenated Calkoxy claim 1 , aryl(C)alkoxy claim 1 , phenyl claim 1 , Calkylthio claim 1 , Calkoxycarbonyl claim 1 , amino claim 1 , cyano claim 1 , hydroxy claim 1 , nitro claim 1 , aminocarbonyl claim 1 , Calkylcarbonylamino claim 1 , and a non fused Ccycloalkyloxy; wherein heteroaryl other than unsubstituted pyridin-2-yl and dihydrobenzofuranyl are optionally substituted with one to three substituents independently selected from the group consisting of Calkyl claim 1 , Calkoxy claim 1 , halogen claim 1 , halogenated Calkyl claim 1 , halogenated Calkoxy claim 1 , aryl(C ...

Подробнее
06-02-2014 дата публикации

SYNTHESIS OF TWO-PHOTON ABSORBING POLYHYDROXY DIPHENYLAMINO-DIALKYLFLUORENE-1,3,5-TRIAZINE MOLECULES

Номер: US20140039185A1

A method of synthesizing a two-photon active tris(diarylamino-9,9-di(R)fluorenyl)-1,3,5-triazine compound having the structure: 2. The method of claim 1 , wherein furnishing bromophenoxy-methyltrimethyl-1 claim 1 ,3-dioxane from the acetonide derivative includes a Mitsunobu reaction.3. The method of claim 1 , wherein furnishing bromophenoxy-methyltrimethyl-1 claim 1 ,3-dioxane from the acetonide derivative includes a copper-catalyzed reaction.4. The method of claim 1 , wherein synthesizing the brominated 1 claim 1 ,3 claim 1 ,5-triazine intermediate further comprises:(1) monoformylating 2,7-dibromo-9,9-di(R)fluorene to form 7-bromo-9,9-di(R)fluorene-2-aldehyde;(2) converting 7-bromo-9,9-di(R)fluorene-2-aldehyde to a nitrile; and(3) catalytically trimerizing the nitrile in trifluoromethanesulfonic acid.5. The method of claim 4 , wherein converting the 7-bromo-9 claim 4 ,9-di(R)fluorene-2-aldehyde to the nitrile includes a hydroxyl-imine intermediate.6. The method of claim 1 , wherein the tris(diarylamino-9 claim 1 ,9-di(R)fluorenyl)-1 claim 1 ,3 claim 1 ,5-triazine compound is tris(diarylamino-9 claim 1 ,9-di(R)fluorenyl)-1 claim 1 ,3 claim 1 ,5-triazine polyhydroxy claim 1 , the method further comprising:treating tris(diarylamino-9,9-di(R)fluorenyl)-1,3,5-triazine polyhydroxy with an acrylic chloride or a methacrylic chloride at a temperature of about 0° C., and with an amine operable as a hydrogen chloride scavenger.12. The method of claim 11 , wherein converting the 7-bromo-9 claim 11 ,9-di(R)fluorene-2-aldehyde to the nitrile includes dehydration of the corresponding hydroxyl-imine intermediate from a condensation reaction with hydroxylamine.13. A method of claim 7 , wherein the tris(diarylamino-9 claim 7 ,9-di(R)fluorenyl)-1 claim 7 ,3 claim 7 ,5-triazine compound is tris(diarylamino-9 claim 7 ,9-di(R)fluorenyl)-1 claim 7 ,3 claim 7 ,5-triazine polyhydroxy claim 7 , the method further comprising:treating tris(di(R)arylamino-9,9-di(R)fluorenyl)-1,3,5-triazine ...

Подробнее
13-02-2014 дата публикации

SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES

Номер: US20140045852A1
Принадлежит:

The present invention relates to substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I). 9. (canceled)10. A pharmaceutical combination comprising a first active ingredient claim 1 , which is a compound according to in combination with one or more further active ingredients.11. A pharmaceutical composition comprising a compound according to in combination with an inert claim 1 , nontoxic claim 1 , pharmaceutically suitable adjuvant.12. A method for the treatment and/or prophylaxis of hyper-proliferative disorders claim 1 , virally induced infectious diseases and/or of cardiovascular diseases in a patient in need thereof claim 1 , comprising administering to the patient a therapeutically effective amount of a compound according to .13. (canceled)16. The compound according to claim 3 , wherein{'sup': '1', 'Rrepresents a group selected from methyl, hydroxyethyl-, propan-2-yl-, cyclopropyl, cyclopentyl; cyclohexyl;'}{'sup': '2', 'claim-text': '4,5-difluoro-2-methoxyphenyl-4-fluoro-2-methoxyphenyl-, 2-(benzyloxy)-4-fluorophenyl-, 3-methoxypyridin-4-yl, 2-[(4-fluorobenzyl)oxy]phenyl-, 2-[(3-fluorobenzyl)oxy]phenyl-, 2-[(3-chlorobenzyl)oxy]phenyl-, 4-chloro-2-(cyclopentyloxy)phenyl-, 5-fluoro-2-[(3-fluorobenzyl)oxy]phenyl-, 2-(cyclopropyloxy)-4-fluorophenyl-, 2-ethoxy-4-fluorophenyl-, 4-fluoro-2-propoxyphenyl-, 2-butoxy-4-fluorophenyl-, 4-fluoro-2-(pentyloxy)phenyl-, 4-fluoro-2-[(4-methylpentyl)oxy]phenyl, 2-(2-cyclopropylethoxy)-4-fluorophenyl-, 4-fluoro-2-[(1-methylcyclopropyl)methoxy]phenyl-, 4-fluoro-2-(3-methylbutoxy)phenyl-, 2-(2-cyclopentylethoxy)-4-fluorophenyl-, 4-fluoro-2-(3- ...

Подробнее
27-02-2014 дата публикации

Electrolyte Additive for Rechargeable Lithium Battery and Rechargeable Lithium Battery Including Same

Номер: US20140057161A1
Принадлежит: Samsung SDI Co Ltd

An electrolyte additive for a rechargeable lithium battery, represented by the following Chemical Formula 1: wherein, R 1 to R 4 are each independently selected from hydrogen, an aliphatic saturated hydrocarbon group, an aliphatic unsaturated hydrocarbon group, an aromatic hydrocarbon group, a heterocyclic group, or a combination thereof, provided that at least one of R 1 or R 2 and at least one of R 3 or R 4 are independently an unsaturated hydrocarbon group including at least one carbon-carbon double bond, and R 5 is selected from hydrogen, a halogen, an aliphatic saturated or unsaturated hydrocarbon group, an aromatic hydrocarbon group, a hydroxyl group, a nitro group, a cyano group, an imino group, an amino group, an amidino group, a hydrazine group, a carboxyl group, a heterocyclic group, or a combination thereof.

Подробнее
27-02-2014 дата публикации

PROCESS FOR TRIMERISING CYCLOALIPHATIC DIISOCYANATES

Номер: US20140058102A1
Принадлежит: Bayer MaterialScience AG

The invention relates to a process for preparing polyisocyanates containing isocyanurate groups by trimerising cycloaliphatic diisocyanates using a catalyst solution comprising at least one quaternary ammonium hydroxide, characterized in that the catalyst solution is metered in such that the reaction temperature is >90° C. and ≦140° C. 1. A process for preparing a polyisocyanate containing isocyanurate groups comprising trimerising a cycloaliphatic diisocyanate in the presence of a catalyst solution comprising at least one quaternary ammonium hydroxide in a reaction solution , wherein the catalyst solution is metered in to said reaction solution such that a reaction temperature of >90° C. and ≦140° C. is maintained.2. The process of claim 1 , wherein the catalyst solution is metered in to said reaction solution such that a reaction temperature of >90° C. and ≦135° C. is maintained.3. The process of claim 1 , wherein the catalyst solution is metered in to said reaction solution such that a reaction temperature of >90° C. and ≦120° C. is maintained.4. The process of claim 1 , wherein the process is carried out continuously in one or more stirred tanks.5. The process of claim 1 , wherein an NCO content is achieved corresponding to a degree of trimerisation of from 8 to 30%.6. The process of claim 1 , wherein an NCO content is achieved corresponding to a degree of trimerisation of from 12 to 24%.7. A continuous process for preparing a polyisocyanate containing isocyanurate groups comprising trimerising a cycloaliphatic diisocyanate in the presence of a catalyst solution comprising at least one quaternary ammonium hydroxide in a stirred tank cascade with n stirred tanks claim 1 , wherein claim 1 , in at least n/2 or (n/2−0.5) tanks claim 1 , the metered addition is such that the reaction temperature in at least n/2 or (n/2+0.5) tanks is >90° C. ands ≦140° C. claim 1 , where n/2 applies to an even number of tanks and (n/2−0.5) or (n/2+0.5) applies to an odd number of ...

Подробнее
13-03-2014 дата публикации

TREATING PROTEIN FOLDING DISORDERS WITH SMALL MOLECULE CFTR CORRECTORS

Номер: US20140073632A1
Принадлежит:

Novel CFTR corrector compounds that are effective in rescuing halide efflux in a cell are provided. Also provided are methods for treating protein folding disorders (e.g., cystic fibrosis). The methods include administering a CFTR corrector compound or pharmaceutically acceptable salt or prodrug thereof. Methods of screening for CFTR corrector compounds are also described herein. The methods of screening include contacting a cell that endogenously expresses a CFTR mutation with the compound to be screened and detecting a rescue of halide efflux from the cell. 158-. (canceled)6058. The method of claim , wherein L is —CH—.6158. The method of claim , wherein L is —CH—CH—.6258. The method of claim , wherein Z is substituted or unsubstituted aryl.6358. The method of claim , wherein the protein folding disorder is cystic fibrosis.65. The method of claim 63 , wherein the protein folding disorder is cystic fibrosis.68. The method of claim 65 , wherein the protein folding disorder is cystic fibrosis. This application claims priority to U.S. Provisional Application No. 61/486,929, filed May 17, 2011, which is incorporated herein by reference in its entirety.This invention was made with government support under Grant Nos. NIDDK R01 DK060065 and NIDDK Phase I SBIR DK084658 awarded by the National Institutes of Health. The government has certain rights in the invention.Cystic fibrosis is an example of a protein folding disorder. It is a hereditary disease caused by mutations in a gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR). The CFTR gene encodes a chloride channel that is expressed in multiple epithelial cell types. A common CFTR mutation, delF508, causes the failure of CFTR to traffic correctly to the plasma membrane because of protein misfolding. The delF508 mutation is estimated to account for 90% of mutant alleles. Because of its high degree of incidence in the cystic fibrosis population, delF508-CFTR is a prime target for cystic fibrosis ...

Подробнее
20-03-2014 дата публикации

CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE INCLUDING THE CONDENSED-CYCLIC COMPOUND

Номер: US20140077175A1
Принадлежит: Samsung Display Co., Ltd.

A condensed-cyclic compound and an organic light-emitting diode including the condensed-cyclic compound. 2. The compound of claim 1 , wherein A1 is a substituted or unsubstituted pyrrolyl group claim 1 , a substituted or unsubstituted pyrazolyl group claim 1 , a substituted or unsubstituted imidazolyl group claim 1 , a substituted or unsubstituted imidazolinyl group claim 1 , a substituted or unsubstituted imidazopyridinyl group claim 1 , a substituted or unsubstituted imidazopyrimidinyl group claim 1 , a substituted or unsubstituted pyridinyl group claim 1 , a substituted or unsubstituted pyrazinyl group claim 1 , a substituted or unsubstituted pyrimidinyl group claim 1 , a substituted or unsubstituted benzoimidazolyl group claim 1 , a substituted or unsubstituted indolyl group claim 1 , a substituted or unsubstituted purinyl group claim 1 , a substituted or unsubstituted quinolinyl group claim 1 , a substituted or unsubstituted phthalazinyl group claim 1 , a substituted or unsubstituted indolizinyl group claim 1 , a substituted or unsubstituted naphthyridinyl group claim 1 , a substituted or unsubstituted quinazolinyl group claim 1 , a substituted or unsubstituted cinnolinyl group claim 1 , a substituted or unsubstituted indazolyl group claim 1 , a substituted or unsubstituted carbazolyl group claim 1 , a substituted or unsubstituted phenazinyl group claim 1 , a substituted or unsubstituted phenanthridinyl group claim 1 , a substituted or unsubstituted pyranyl group claim 1 , a substituted or unsubstituted chromenyl group claim 1 , a substituted or unsubstituted furanyl group claim 1 , a substituted or unsubstituted benzofuranyl group claim 1 , a substituted or unsubstituted thiophenyl group claim 1 , a substituted or unsubstituted benzothiophenyl group claim 1 , a substituted or unsubstituted isothiazolyl group claim 1 , a substituted or unsubstituted benzoimidazolyl group claim 1 , a substituted or unsubstituted isoxazolyl group claim 1 , a substituted or ...

Подробнее
10-04-2014 дата публикации

METHODS AND COMPOSITIONS FOR TREATING ANXIETY

Номер: US20140100230A1
Принадлежит: HYDRA BIOSCIENCES, INC.

Methods of treating a TRPC5 mediated disorder in a subject by administering an effective amount of a TRPC5 antagonist, such as a compound disclosed herein, are described. 1. A method of treating a TRPC5 mediated disorder in a subject , the method comprising administering an effective amount of a TRPC5 antagonist.2. The method of claim 1 , wherein the TRPC5 mediated disorder is pain.3. The method of claim 1 , wherein the TRPC5 mediated disorder is anxiety.4. The method of claim 1 , wherein the TRPC5 mediated disorder is epilepsy. This applications claims priority from U.S. Ser. No. 61/086,784; U.S. Ser. No. 61/086,785; and U.S. Ser. No. 61/086,787, all of which were filed Aug. 6, 2008, and are hereby incorporated by reference in their entireties.A variety of ion channel proteins exist to mediate ion flux across cellular membranes. The proper expression and function of ion channel proteins is essential for the maintenance of cell function, intracellular communication, and the like. Numerous diseases are the result of misregulation of membrane potential or aberrant calcium handling. Given the central importance of ion channels in modulating membrane potential and ion flux in cells, identification of agents that can promote or inhibit particular ion channels are of great interest as potential therapeutic agents.The present invention provides methods and compositions for treating conditions such as pain and/or anxiety by modulating the activity of the transient receptor potential cation channel subfamily C, member 5 (TRPC5), which can exist in homomultimeric form as well as heteromultimeric form with other ion channels such as TRPC1 or TRPC3 (i.e., TRPC5-TRPC1 and TRPC1-TRPC3-TRPC5). The compounds described herein modulate the function of TRPC5 by inhibiting a TRPC5-mediated ion flux or by inhibiting the inward current, the outward current, or both currents mediated by TRPC5. The inhibition of a particular current is the ability to inhibit or reduce such current (e.g., ...

Подробнее
06-01-2022 дата публикации

METHODS OF TREATMENT OF MALIGNANCIES

Номер: US20220000878A1
Автор: Choe Sung Eun, Wu Bin
Принадлежит:

Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation or IDH2 mutation. 2. The method of claim 1 , wherein the RAS mutation is an NRAS mutation.3. The method of claim 1 , wherein the RAS mutation is a KRAS mutation.46-. (canceled)8. The method of claim 7 , wherein the RAS mutation is an NRAS mutation.9. The method of claim 7 , wherein the RAS mutation is a KRAS mutation.1012-. (canceled)13. The method of claim 7 , wherein the IDH1 mutation is an IDH1 R132X mutation.14. The method of claim 13 , wherein the IDH1 mutation is an IDH1 R132H claim 13 , R132C claim 13 , R132L claim 13 , R132V claim 13 , R132S or R132G mutation.15. The method of claim 7 , wherein the RAS pathway inhibitor is a MEK kinase inhibitor.16. The method of claim 15 , wherein the MEK kinase inhibitor is selected from trametinib claim 15 , selumetinib claim 15 , binimetinib claim 15 , PD-325901 claim 15 , cobimetinib claim 15 , CI-1040 and PD035901.17. (canceled)18. The method of claim 7 , wherein the acute myelogenous leukemia (AML) is relapsed or refractory.19. (canceled)20. The method of claim 7 , wherein the dose of COMPOUND 2 is about 20 to about 2000 mg/day.21. The method of claim 7 , wherein the dose of COMPOUND 2 is about 50 to 500 mg/day.2262-. (canceled)63. The method of claim 7 , wherein the dose of COMPOUND 2 is about 500 mg/day.64. The method of claim 1 , wherein the IDH1 mutation is an IDH1 R132X mutation.65. The method of claim 64 , wherein the IDH1 mutation is an IDH1 R132H claim 64 , R132C claim 64 , R132L claim 64 , R132V claim 64 , R132S or R132G mutation.66. The method of claim 1 , wherein the acute myelogenous leukemia (AML) is relapsed or refractory.67. The method of claim 1 , wherein the dose of COMPOUND 2 is about 20 to about 2000 mg/day.68. The method of claim 1 , wherein the dose of COMPOUND 2 is about 50 to 500 mg/day.69. The method of claim 1 , wherein the dose of COMPOUND 2 is about 500 mg/day. This application is a continuation ...

Подробнее
06-01-2022 дата публикации

TRIAZINANES AND METHODS OF MAKING THEM

Номер: US20220002256A1
Принадлежит: FLEXSYS AMERICA L.P.

The present invention is directed to compounds represented by the formula: Formula (i) wherein Rcomprises a hydrogen atom or an alkyl group having 1 to 2 carbon atoms; wherein Rcomprises an alkylene group, an arylene group, or a heterocyclic group; and wherein M comprises a monovalent metallic cation such as sodium, lithium, or potassium; or a multivalent metallic cation such as zinc, nickel, iron, titanium, or cobalt; or an ammonium or alkyl ammonium cation derived by addition of proton (s) to a nitrogenous base. 2. The compound of claim 1 , wherein R1 comprises a hydrogen atom;wherein R2 comprises an alkylene group having from 1 to 5 carbon atoms; andwherein M comprises a monovalent metallic cation.3. The compound of claim 1 , wherein R1 comprises hydrogen;wherein R2 comprises an alkylene group having from 1 to 3 carbon atoms; andwherein M comprises a monovalent metallic cation or an ammonium or alkyl ammonium cation derived by addition of one or more protons to a nitrogenous base.4. Sodium S claim 1 ,S′ claim 1 ,S″-((1 claim 1 ,3 claim 1 ,5-triazinane-1 claim 1 ,3 claim 1 ,5-triyl)tris(ethane-2 claim 1 ,1-diyl)) tris(sulfurothioate).5. Sodium S claim 1 ,S′ claim 1 ,S″-((1 claim 1 ,3 claim 1 ,5-triazinane-1 claim 1 ,3 claim 1 ,5-triyl)tris(propane-3 claim 1 ,1-diyl)) tris(sulfurothioate).6. Sodium S claim 1 ,S′ claim 1 ,S″-((1 claim 1 ,3 claim 1 ,5-triazinane-1 claim 1 ,3 claim 1 ,5-triyl)tris(butane-4 claim 1 ,1-diyl)) tris(sulfurothioate).7. Sodium S claim 1 ,S′ claim 1 ,S″-((1 claim 1 ,3 claim 1 ,5-triazinane-1 claim 1 ,3 claim 1 ,5-triyl)tris(pentane-5 claim 1 ,1-diyl)) tris(sulfurothioate).8. A method of making the compound of claim 1 , comprising:reacting a haloalkylamine hydrohalide with a metal thiosulfate to obtain an alkylammonium halide thiosulfate metal salt;deprotonating the alkylammonium halide thiosulfate metal salt to obtain an alkylammonium thiosulfate metal salt; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'reacting the alkylammonium ...

Подробнее
04-01-2018 дата публикации

Catalysts for Producing Isocyanurates from Isocyanates

Номер: US20180001310A1
Принадлежит:

The invention relates to a method for producing isocyanurates and isocyanurate-containing polyurethanes, comprising the step of reacting an isocyanate in the presence of a catalyst. 1. A process for producing isocyanurates and isocyanurate-containing polyurethanes comprising reacting an isocyanate in the presence of a catalyst ,wherein:the catalyst comprises the product of the reaction of a thiol group containing carboxylic acid with an alkali metal, alkaline earth metal, scandium-group or lanthanoid base,wherein the reaction is performed in the absence of compounds comprising tin or lead,wherein the degree of deprotonation of the catalyst is ≧50% to ≦100% and the H atoms present in carboxyl groups as well as the carboxylate groups and the H atoms present in thiol groups as well as the thiolate groups are considered when calculating the degree of deprotonation.2. The process as claimed in claim 1 , wherein the thiol group containing carboxylic acid comprises a thiol group and a carboxyl group.3. The process as claimed in claim 2 , wherein the thiol group containing carboxylic acid is selected from the group consisting of 2-mercaptoacetic acid claim 2 , 3-mercaptopropionic acid claim 2 , 4-mercaptobutyric acid claim 2 , thiosalicylic acid claim 2 , and combinations of any thereof.4. The process as claimed in claim 1 , wherein the degree of deprotonation of the catalyst is ≧70% to ≦100% and the H atoms present in carboxyl groups as well as the carboxylate groups and the H atoms present in thiol groups as well as the thiolate groups are considered when calculating the degree of deprotonation.5. The process as claimed in claim 1 , wherein the base for deprotonating the catalyst precursor is selected from the group consisting of an alkali metal claim 1 , alkaline earth metal claim 1 , scandium-group or lanthanoid hydride claim 1 , an alkali metal claim 1 , alkaline earth metal claim 1 , scandium-group or lanthanoid alkoxide or an alkali metal claim 1 , alkaline earth ...

Подробнее
07-01-2016 дата публикации

METHOD FOR PRODUCING A POLYMERIZABLE UV ABSORBER

Номер: US20160002181A1
Принадлежит:

The present invention relates to a two-stage preparation process for an organic UV absorber that has a (meth)acrylate group in the molecule and which as a result is particularly suitable for curable UV protective coatings. One example of the preparation process is: 17.-. (canceled)9. The process according to claim 8 , wherein X is CH(CH).10. The process according to claim 8 , wherein r in each of the substituents Yand Yis 1.11. The process according to claim 8 , wherein the radicals R claim 8 , Rand Rin each of the substituents Yand Yare H.12. The process according to claim 8 , wherein the reducing of the compound (II) to the compound (IIa) takes place with a complex hydride as reducing agent.13. The process according to claim 8 , wherein the reducing of the compound (II) to the compound (IIa) is carried in a solvent mixture comprising tetrahydrofuran and an alcohol.14. The process according to claim 8 , wherein the reacting of the compound (IIa) takes place with (meth)acrylic acid and/or (meth)acrylic esters and in the presence of benzenesulfonic acid and/or toluenesulfonic acid as catalyst. The present invention relates to the preparation process for an organic UV absorber which has a (meth)acrylate group in the molecule and which as a result is particularly suitable for curable UV protective coatings.For exterior applications it is necessary to protect transparent plastics articles, such as sheets, films, injection-moulded components or extrusion mouldings, for example, especially by means of UV protection, against aggressive solar radiation and, by means of scratch-proofing, against mechanical exposures. One common method for accomplishing this is to endow the top and in some cases also the only protective layer, which must be scratch-resistant, with UV protective function, additionally, and to do this by equipping it with a substantial quantity of UV absorbers (cf. DE-A 10 2006 016 642). Within the protective layers, however, the conventional UV absorbers act ...

Подробнее
04-01-2018 дата публикации

DOUBLE-SPIRO TYPE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE CONTAINING SAME

Номер: US20180002256A1
Автор: Cha Yongbum, Kim Jin Joo
Принадлежит:

The present specification relates to a double spiro structure compound, and an organic light emitting device comprising the same. 3. The double spiro structure compound of claim 1 , wherein Cy1 is a substituted or unsubstituted benzene ring.4. The double spiro structure compound of claim 1 , wherein Lto Lare the same as or different from each other and each independently a direct bond; a substituted or unsubstituted phenylene group; or a substituted or unsubstituted biphenylylene group.5. The double spiro structure compound of claim 1 , wherein Arto Arare the same as or different from each other claim 1 , and each independently selected from the group consisting of a substituted or unsubstituted phenyl group; a substituted or unsubstituted biphenylyl group; a substituted or unsubstituted naphthyl group; a substituted or unsubstituted terphenyl group; a substituted or unsubstituted quaterphenyl group; a substituted or unsubstituted fluorenyl group; a substituted or unsubstituted phenanthrenyl group; a substituted or unsubstituted terphenylenyl group; a substituted or unsubstituted dibenzothiophene group; and a substituted or unsubstituted dibenzofuran group.13. An organic light emitting device comprising:an anode;a cathode provided opposite to the anode; anda light emitting layer and one or more organic material layers provided between the anode and the cathode,{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'wherein the light emitting layer or one or more layers of the organic material layers comprise the double spiro structure compound of .'}14. The organic light emitting device of claim 13 , wherein the organic material layer comprises a hole injection layer or a hole transfer layer claim 13 , and the hole injection layer or the hole transfer layer comprises the double spiro structure compound.15. The organic light emitting device of claim 13 , wherein the organic material layer comprises an electron blocking layer claim 13 , and the electron blocking layer ...

Подробнее
06-01-2022 дата публикации

COMPOUNDS THAT CAN BE USED FOR PRODUCING AN ORGANIC ELECTRONIC DEVICE

Номер: US20220006018A1
Автор: Stoessel Philipp
Принадлежит:

The invention relates to compounds that can be used for producing functional layers of electronic devices, in particular for use in electronic devices. The invention further relates to a process for preparing the compounds according to the invention, and to electronic devices comprising same. 3. The compound as claimed in wherein the organofunctional compound usable for production of functional layers of electronic devices is selected from the group consisting of fluorescent emitters claim 1 , phosphorescent emitters claim 1 , emitters that exhibit TADF (thermally activated delayed fluorescence) claim 1 , host materials claim 1 , electron transport materials claim 1 , exciton blocker materials claim 1 , electron injection materials claim 1 , hole conductor materials claim 1 , hole injection materials claim 1 , n-dopants claim 1 , p-dopants claim 1 , wide band gap materials claim 1 , electron blocker materials and hole blocker materials.4. The compound of claim 1 , wherein the organofunctional compound is selected from the group of the fluorenes claim 1 , indenofluorenes claim 1 , spirobifluorenes claim 1 , carbazoles claim 1 , indenocarbazoles claim 1 , indolocarbazoles claim 1 , spirocarbazoles claim 1 , pyrimidines claim 1 , triazines claim 1 , lactams claim 1 , triarylamines claim 1 , dibenzofurans claim 1 , dibenzothiophenes claim 1 , dibenzothienes claim 1 , imidazoles claim 1 , benzimidazoles claim 1 , benzoxazoles claim 1 , benzothiazoles claim 1 , 5-arylphenanthridin-6-ones claim 1 , 9 claim 1 ,10-dehydrophenanthrenes claim 1 , fluoranthenes claim 1 , anthracenes claim 1 , benzanthracenes claim 1 , and fluoradenes.6. The compound of claim 1 , wherein the organofunctional compound comprises at least one hole transport group.7. The compound of claim 1 , wherein the organofunctional compound comprises at least one electron transport group.8. The compound of claim 1 , wherein the organofunctional compound comprises at least one group that leads to wide bandgap ...

Подробнее
04-01-2018 дата публикации

Fluorene Derivatives as Light Emitting Elements for Electroluminescent Devices

Номер: US20180002597A1
Принадлежит:

The present disclosure provides a composition comprising at least one compound selected from the group consisting of Compound 1, Compound 2, and combinations thereof, as shown below, and described herein: wherein, for Compound 1 and Compound 2, independently, Rand Reach independently is selected from the group consisting of hydrogen, a substituted alkyl, an unsubstituted alkyl, a substituted heteroalkyl, an unsubstituted heteroalkyl, a substituted aryl, an unsubstituted aryl, a substituted heteroaryl and an unsubstituted heteroaryl; wherein, for Compound 1 and Compound 2, independently, the Component A is selected from the group consisting of Group a) through Group h): wherein Group a) through Group h) are described herein. 2. The composition of claim 1 , wherein the composition comprises Compound 1 claim 1 , and Rand Rfor Compound 1 each independently is selected from the group consisting of a substituted aryl claim 1 , an unsubstituted aryl claim 1 , a substituted heteroaryl claim 1 , and an unsubstituted heteroaryl.3. The composition of claim 2 , wherein the composition comprises Compound 1 claim 2 , and Rand Rfor Compound 1 each independently is selected from the group consisting of an unsubstituted aryl and an unsubstituted heteroaryl.9. The composition of claim 1 , wherein the composition comprises Compound 2 claim 1 , and wherein for Compound 2 claim 1 , Rand Reach independently is selected from the group consisting of a substituted aryl claim 1 , unsubstituted aryl claim 1 , a substituted heteroaryl claim 1 , and an unsubstituted heteroaryl.15. An electronic device comprising at least one component formed the composition of . This application claims priority to U.S. provisional patent application No. 62/097,720 filed on 30 Dec. 2014, the entire content of which is incorporated by reference herein.An OLED (organic light-emitting diode) is a light-emitting diode (LED), in which the emissive electroluminescent layer is a film of an organic compound, which emits ...

Подробнее
02-01-2020 дата публикации

HEAT-STORAGE MATERIAL COMPRISING METAL SALT OF CYANURIC ACID

Номер: US20200002591A1
Автор: Yoshino Hironobu
Принадлежит: NISSAN CHEMICAL CORPORATION

A heat-storage material, in particular a chemical heat-storage material, adsorbs or desorbs water vapor (water) at a low temperature (i.e., usable at a low temperature) and stores a large amount of heat. A chemical heat-storage material includes a cyanuric acid metal salt, wherein the chemical heat-storage material generates or absorbs heat by adsorption or desorption of water vapor (water). 1. A chemical heat-storage material comprising a cyanuric acid metal salt , wherein the chemical heat-storage material generates or absorbs heat by adsorption or desorption of water vapor (water).2. The chemical heat-storage material according to claim 1 , wherein the metal species of the metal salt is at least one selected from the group consisting of lithium claim 1 , sodium claim 1 , potassium claim 1 , magnesium claim 1 , calcium claim 1 , strontium claim 1 , barium claim 1 , aluminum claim 1 , manganese claim 1 , iron claim 1 , cobalt claim 1 , copper claim 1 , nickel claim 1 , zinc claim 1 , silver claim 1 , and tin.3. The chemical heat-storage material according to claim 2 , wherein the metal species of the metal salt is an alkaline earth metal.4. The chemical heat-storage material according to claim 2 , wherein the metal species of the metal salt is at least one selected from the group consisting of magnesium and calcium.5. The chemical heat-storage material according to claim 4 , wherein the ratio by mole of cyanuric acid to at least one selected from the group consisting of magnesium and calcium is 2:1.6. The chemical heat-storage material according to claim 1 , wherein the amount of heat generated by adsorption of water vapor (water) or the amount of heat absorbed by desorption of water vapor (water) is 0.5 MJ/kg or more.7. The chemical heat-storage material according to claim 1 , wherein the chemical heat-storage material exhibits a desorption temperature of water vapor (water) of 200° C. or lower.8. A heat exchanger comprising the chemical heat-storage material ...

Подробнее
04-01-2018 дата публикации

SPIRO-TYPE COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME

Номер: US20180006233A1
Принадлежит: LG CHEM, LTD.

The present specification provides a compound having a spiro structure, and an organic light emitting device including the same. 3. The compound of claim 1 , wherein HAr is a substituted or unsubstituted pyridyl group; a substituted or unsubstituted pyrimidyl group; a substituted or unsubstituted triazinyl group; a substituted or unsubstituted furan group; a substituted or unsubstituted thiophene group; a substituted or unsubstituted oxadiazole group; a substituted or unsubstituted thiadiazole group; a substituted or unsubstituted phenanthroline group; a substituted or unsubstituted quinolinyl group; a substituted or unsubstituted isoquinolinyl group; a substituted or unsubstituted quinazoline group; a substituted or unsubstituted benzoxazole group; a substituted or unsubstituted benzothiazole group; a substituted or unsubstituted benzimidazole group; a substituted or unsubstituted phenoxazine group; a substituted or unsubstituted phenothiazine group; a substituted or unsubstituted dibenzofuran group; a substituted or unsubstituted dibenzothiophene group; a substituted or unsubstituted carbazole group; or a substituted or unsubstituted diarylphosphine oxide group.7. An organic light emitting device comprising:a first electrode;a second electrode provided opposite to the first electrode; andone or more organic material layers provided between the first electrode and the second electrode,{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'wherein one or more layers of the organic material layers include the compound of .'}8. The organic light emitting device of claim 7 , wherein the organic material layer includes a light emitting layer claim 7 , and the light emitting layer includes the compound.9. The organic light emitting device of claim 8 , wherein the light emitting layer further includes a light emitting dopant.10. The organic light emitting device of claim 7 , wherein the organic material layer includes an electron injection layer claim 7 , an electron transfer ...

Подробнее
04-01-2018 дата публикации

COMPOSITION FOR ORGANIC PHOTOELECTRONIC ELEMENT, ORGANIC PHOTOELECTRONIC ELEMENT, AND DISPLAY APPARATUS

Номер: US20180006238A1
Принадлежит:

The present invention relates to: a composition for an organic photoelectronic element comprising at least one type of a first chemical compound represented by chemical formula 1 and at least one type of a second chemical compound represented by chemical formula 2; an organic photoelectronic element comprising the same; and a display apparatus comprising said organic photoelectronic element. Chemical formulas 1 and 2 are described in the specification of the present invention. 3. The composition for an organic optoelectronic device of claim 1 , wherein the Lis a phenylene group that is unsubstituted or substituted with deuterium claim 1 , a C1 to C40 silyl group claim 1 , a C1 to C30 alkyl group claim 1 , or a C6 to C30 aryl group;a biphenylene group that is unsubstituted or substituted with deuterium, a C1 to C40 silyl group, a C1 to C30 alkyl group, or a C6 to C30 aryl group;a terphenylene group that is unsubstituted or substituted with deuterium, a C1 to C40 silyl group, a C1 to C30 alkyl group, or a C6 to C30 aryl group; ora quarterphenylene group that is unsubstituted or substituted with deuterium, a C1 to C40 silyl group, a C1 to C30 alkyl group, or a C6 to C30 aryl group.5. The composition for an organic optoelectronic device of claim 1 , wherein Xto Xof Chemical Formula 1 are independently N claim 1 , C claim 1 , or CR claim 1 ,{'sup': 1', '6, 'three of Xto Xare N,'}{'sup': 7', '12, 'one to three of Xto Xare N,'}{'sup': 'a', 'Ris independently, hydrogen, deuterium, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C6 to C30 aryl group, a substituted or unsubstituted C2 to C30 heteroaryl group, or a combination thereof, and'}{'sup': '1', 'Lis a C6 to C30 arylene group that is substituted or unsubstituted with deuterium, a C1 to C30 alkyl group, or a C6 to C30 aryl group,'}wherein “substituted” refers to that at least one hydrogen is replaced by deuterium, a halogen, a hydroxy group, a C1 to C40 silyl group, a C1 to C30 alkyl ...

Подробнее
20-01-2022 дата публикации

CONJUGATES OF BIVALENT EVANS BLUE DYE DERIVATIVES AND METHODS OF USE

Номер: US20220017495A1
Принадлежит:

A compound of Formula (I) or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt, is disclosed. Compositions comprising the compound and methods of use are also disclosed. Those dimeric Evans Blue derivatives, denoted as N(tEB)2, reversibly bind two molecules of albumin via the two albumin binding regions of each NtEB in the dimer, resulting in significantly increased binding affinity to albumin and extended circulation half-life in vivo. Further, when the N(tEB)2 is conjugated to a peptide therapeutic, the in situ formation of the complex of N(tEB)2 with two albumin molecules resulted in increased resistance of the peptide therapeutic from proteolysis. 2. The compound of claim 1 , wherein Rand Rare chosen independently from halogen claim 1 , hydroxyl claim 1 , cyano claim 1 , C-Calkyl claim 1 , C-Calkoxy claim 1 , C-Chaloalkyl claim 1 , and C-Chaloalkoxy.3. (canceled)4. The compound of claim 1 , wherein Rand Rare each methyl claim 1 , and R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Ru are each hydrogen.5. The compound of claim 1 , wherein{'sub': 1', '2', '2', '4', '3', '3', '2', '12, 'Ais —NH(CS)NH—, Ais —(CO)NH—, and B is —(CH)CH(A)- wherein Ais (-LR) and'}{'sub': 2', '2, 'Lis —NH(CO)CH—;'}{'sub': 1', '2', '2', '2', '3', '3', '2, 'Ais —NH(CO)—, Ais —(CO)NH—, and B is —(CH)CH(A)- wherein Ais —NH; or'}{'sub': 1', '2', '2', '3', '2', '3', '2, 'Ais —NH(CO)—, Ais —(CO)NH—, and B is —CHCH(A)CH— wherein Ais —NH.'}9. The compound of wherein independently each of m and k is an integer from 0 to 2 claim 1 , preferably m=0 claim 1 , k=0.10. The compound of claim 1 , wherein Ais —COOH.16. The compound of claim 15 , wherein the radionuclide is F claim 15 , Br claim 15 , I claim 15 , I claim 15 , a claim 15 , Cu claim 15 , Cu claim 15 , Y claim 15 , Y claim 15 , In claim 15 , Re claim 15 , Re claim 15 , Zr claim 15 , Tc claim ...

Подробнее
03-01-2019 дата публикации

Novel compound, material for organic electroluminescence device, and organic electroluminescence device

Номер: US20190006598A1
Принадлежит: Idemitsu Kosan Co Ltd

A compound represented by the following formula (1):

Подробнее
11-01-2018 дата публикации

Compositions and Methods for Treating Metabolic Disorders

Номер: US20180008561A1
Принадлежит:

Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine. 1. A method of improving the gastrointestinal tolerability of and/or reducing gastrointestinal complications resulting from biguanide administration , comprising administering a therapeutically effective amount of a biguanide compound in a delayed-release formulation to a patient in need thereof.2. A method of treating metabolic disorders in a patient in need thereof , comprising administering a therapeutically effective amount of a biguanide compound to said patient in a delayed-release formulation , wherein said patient has a contraindication for the biguanide compound.3. The method according to claim 2 , wherein the patient has a contraindication selected from the group consisting of a hypoxic condition claim 2 , impaired lactate clearance claim 2 , and impaired clearance of the biguanide compound.4. The method according to claim 3 , wherein the patient has a hypoxic condition.5. The method according to claim 3 , wherein the patient has impaired lactate clearance.6. The method according to claim 3 , wherein the patient has impaired clearance of the biguanide compound.7. The method according to claim 3 , wherein the patient has moderate renal impairment claim 3 , severe renal impairment claim 3 , or endstage renal disease which results in impaired clearance of the biguanide compound.8. The method according to claim 3 , wherein the patient has chronic kidney disease.9. The method according to any one of the preceding claims claim 3 , wherein the patient in need thereof has hyperglycemia.10. The method according to claim 9 , wherein the hyperglycemia is ...

Подробнее
11-01-2018 дата публикации

PROSTAGLANDIN TRANSPORTER INHIBITORS FOR INHIBITING OVULATION

Номер: US20180008569A1
Принадлежит:

The present invention provides methods and compositions for inhibiting ovulation in a female subject, including a subject in need of contraceptives and a subject undergoing fertility treatments. The methods comprise administering to the female subject at least one prostaglandin transporter (PGT) inhibitor. 130-. (canceled)31. A method for inhibiting ovulation in a female subject , comprising administering to said female subject a pharmaceutical composition comprising at least one prostaglandin transporter (PGT) inhibitor.32. The method of claim 31 , wherein said PGT inhibitor is capable of inhibiting at least one of oocyte nuclear maturation claim 31 , cumulus expansion or follicular rupture.33. The method of claim 31 , wherein said pharmaceutical composition is administered daily from one to four days prior to a mid-cycle.34. The method of claim 33 , wherein said pharmaceutical composition is administered daily during the mid-cycle and at least one day thereafter.35. The method of claim 31 , wherein said pharmaceutical composition is administered daily from day 9 of a menstrual cycle to day 14 of the menstrual cycle.36. The method of claim 31 , further comprising measuring a luteinizing hormone (LH) level.37. The method of claim 36 , further comprising administering said pharmaceutical composition daily claim 36 , from a day that the LH level surges until claim 36 , and including claim 36 , a day that LH level drops to baseline.38. The method of claim 31 , further comprising measuring estradiol levels.39. The method of claim 38 , further comprising administering said pharmaceutical composition daily claim 38 , at a day that the estradiol level surges and at least four consecutive days thereafter.40. The method of claim 31 , further comprising measuring a level of estradiol and luteinizing hormone (LH) and administering said pharmaceutical composition daily from a day that the level of estradiol surges and until a day that the level of LH drops to baseline.41. The ...

Подробнее
11-01-2018 дата публикации

SYNTHESIS OF TRIACETONEDIAMINE COMPOUNDS BY REDUCTIVE AMINATION PROCEEDING FROM TRIACETONEDIAMINE AND DERIVATIVES THEREOF

Номер: US20180009734A1
Принадлежит: EVONIK DEGUSSA GmbH

An N-substituted triacetonediamine compound is produced by reacting 4-amino-2,2,6,6-tetramethylpiperidine or a derivative thereof with a carbonyl compound in a reductive amination. 2. The process according to claim 1 , wherein p=p=p=p=p=p=p=p=p=p=0 and wherein p claim 1 , p claim 1 , p claim 1 , p claim 1 , p claim 1 , pare each independently 0 or 1.3. The process according to claim 1 , wherein Y claim 1 , Y claim 1 , Y claim 1 , Y claim 1 , Y claim 1 , Y claim 1 , Y claim 1 , Y claim 1 , Yare each independently selected from the group consisting ofunbranched or branched alkylene group having 1 to 30 carbon atoms, anddivalent saturated hydrocarbyl group having 3 to 30 carbon atoms and having at least one saturated ring composed of 3 to 30 carbon atoms.5. The process according to claim 1 , wherein X=X=X=X=XXX=X=X=X=X=X claim 1 , X=X=X=hydrogen.6. The process according to claim 1 , wherein the triacetonediamine compound (I) is selected from the group consisting of the chemical structures (I-A) claim 1 , and (I-B) and wherein the R claim 1 , Rradicals are each independently selected from the group consisting ofhydrogen, and{'sub': 2', '3', '2', '3', '3', '3', '2', '2', '3', '2', '3', '2', '3', '2', '3, 'unbranched or branched alkyl group which has 1 to 12 carbon atoms and in which at least one hydrogen radical may be replaced by a radical selected from the group consisting of —OH, —NH, —OCH, —OCHCH, —NH(CH), —N(CH), —NH(CHCH), —N(CHCH), and —N(CH)(CHCH).'}7. The process according to claim 1 , wherein the triacetonediamine compound (I) is selected from the group consisting of the chemical structures (I-A) claim 1 , and (I-B) and wherein the R′ claim 1 , Rradicals are each independently selected from the group consisting ofhydrogen, andunbranched or branched alkyl group having 1 to 12 carbon atoms.8. The process according to claim 1 , wherein Z claim 1 , Z claim 1 , Zare each independently selected from the group consisting ofdirect bond, and 'divalent saturated ...

Подробнее
14-01-2021 дата публикации

COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME

Номер: US20210009527A1
Принадлежит: IDEMITSU KOSAN CO.,LTD.

A compound represented by the following formula (1), wherein Xis O or S, and two or more of Y, Yand Yare N, provided that the case where one or both of —Ar—Arand —Ar—Aris a p-terphenyl-3-yl group is excluded. 2. The compound according to claim 1 , wherein Arand Arare independentlyan unsubstituted phenyl group,a substituted or unsubstituted naphthyl group,a substituted or unsubstituted phenanthryl group, ora substituted or unsubstituted anthryl group.3. The compound according to or claim 1 , wherein{'sub': 1', '3', '2', '4, 'when Arand Arare an unsubstituted phenylene group, Arand Arare independently'}an unsubstituted phenyl group,a substituted or unsubstituted naphthyl group,a substituted or unsubstituted phenanthryl group, ora substituted or unsubstituted anthryl group.4. The compound according to claim 1 , wherein Arand Are claim 1 , and Arand Arindependently do not form a ring by bonding with each other.5. The compound according to claim 1 , wherein{'sub': 1', '4, 'when Arto Arare substituted by a substituent, the substituent is'}an unsubstituted phenyl group,an unsubstituted naphthyl group,an unsubstituted phenanthryl group,an unsubstituted anthryl group,an unsubstituted biphenyl group,an unsubstituted alkyl group including 1 to 50 carbon atoms, oran unsubstituted cycloalkyl group including 3 to 50 ring carbon atoms.10. the compound according to claim 6 ,{'sub': 'a', "wherein the one or more sets of adjacent two or more R's do not form a ring by bonding with each other."}11. The compound according to claim 1 , wherein Arand Arare independentlyan unsubstituted phenyl group,an unsubstituted naphthyl group,an unsubstituted anthryl group, oran unsubstituted phenanthryl group.12. The compound according to claim 1 , wherein Xis S.13. The compound according to claim 1 , wherein Yto Yare N.23. An electron-transporting material for an organic electroluminescence device claim 1 , which comprises the compound according to .24. An organic electroluminescence device ...

Подробнее
14-01-2021 дата публикации

METHODS FOR TREATING PROTOZOAN INFECTIONS

Номер: US20210009552A1
Принадлежит:

The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufacture of a medicament for the treatment of a protozoan infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a protozoan infection in a subject and to a medical device comprising the composition of the invention. 141.-. (canceled)43. A composition comprising the compound of .44. A pharmaceutical or veterinarian composition comprising the compound of and a pharmaceutically acceptable excipient.45. The compound of claim 42 , wherein the compound is 4 claim 42 ,6-bis(2-((E)-(6-chloropyridin-3-yl)methylene)hydrazinyl)pyrimidin-2-amine or a stereoisomer claim 42 , tautomer claim 42 , pharmaceutically acceptable salt thereof.46. The compound of claim 42 , wherein the compound is 4 claim 42 ,6-bis(2-((E)-pyridin-3-ylmethylene)hydrazinyl)pyrimidin-2-amine or a stereoisomer claim 42 , tautomer claim 42 , pharmaceutically acceptable salt thereof.47. The compound of claim 42 , wherein the compound is 4 claim 42 ,6-bis(2-((E)-pyridin-2-ylmethylene)hydrazinyl)pyrimidin-2-amine or a stereoisomer claim 42 , tautomer claim 42 , pharmaceutically acceptable salt thereof.48. The compound of claim 42 , wherein the compound is 4 claim 42 ,6-bis(2-((E)-pyridin-4-ylmethylene)hydrazinyl)pyrimidin-2-amine or a stereoisomer claim 42 , tautomer claim 42 , pharmaceutically acceptable salt thereof.49. The compound of claim 42 , wherein the compound is 4 claim 42 ,6-bis(2-((E)-2 claim 42 ,5-dihydroxybenzylidene)hydrazinyl)pyrimidin-2-aminium 2-formyl-4-hydroxyphenolate or a stereoisomer claim 42 , tautomer claim 42 , pharmaceutically acceptable salt thereof.50. The compound of claim 42 , wherein the compound is 4 claim 42 ,6-bis(2-((E)-3 claim 42 ,4-dihydroxybenzylidene)hydrazinyl) ...

Подробнее
08-01-2015 дата публикации

NOVEL TRIAZINE DERIVATIVE

Номер: US20150011751A1
Принадлежит:

To provide a novel triazine derivative represented by the following formula (I): The present invention relates to a pharmaceutical, and particularly to a novel triazine derivative having a BTK inhibitory effect, or a pharmaceutically acceptable salt thereof.Bruton's tyrosine kinase (BTK) is a member of the Tec family of non-receptor tyrosine kinases, and is an important signaling enzyme which is expressed in all hematopoietic cell types except for T lymphocytes and natural killer cells. BTK is an important control factor associated with survival, differentiation, proliferation and activation of B-cells, and takes an important role in signaling of B-cells (Non Patent Literatures 1 and 2). A B-cell receptor (BCR) of the cell surface signals into cells through BTK existing in the downstream of BCR and, therefore, it is considered that abnormal activation of the signaling pathway of B-cells accelerates proliferation and survival of cancer cells of B-cell lymphoma, chronic lymphocytic leukemia and the like (Non Patent Literature 3). It is known that BTK also plays an important role in the signal pathway of a large number of other cells, and it is said that BTK is involved in allergic diseases, self-immune diseases, inflammatory diseases and the like (Non Patent Literature 1). For example, it is known that BTK plays an important role for signaling of a high affinity IgE receptor (FcεRI) in mast cells, and degranulation decreases and the production of proinflammatory cytokines decreases in BTK-deficient mast cells (Non Patent Literature 4). It is suggested that BTK is involved in systemic lupus erythematosus (SLE) in a test of a BTK-deficient mouse (Non Patent Literature 5). Furthermore, the BTK mutant mouse exhibits resistance to the onset of collagen-induced arthritis (Non Patent Literature 6). Therefore, the compound having a BTK inhibitory activity is useful for the treatment of diseases which are involved in BTK signaling, for example, cancer, B-cell lymphoma, and ...

Подробнее
08-01-2015 дата публикации

TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS

Номер: US20150011752A1
Принадлежит:

Compounds of formula I 145-. (canceled) This invention relates to 2,4,6-substituted [1,3,5]triazine compounds in which one substituent is an optionally substituted morpholino, tetrahydropyranyl or dihydropyranyl group, which inhibit PI3 kinase and mTOR, to processes for preparing them, to methods of treatment using them and to pharmaceutical compositions containing them.Phosphatidylinositol (hereinafter abbreviated as “PI”) is one of the phospholipids in cell membranes. In recent years it has become clear that PI plays an important role also in intracellular signal transduction. It is well recognized in the art that PI (4,5) bisphosphate (PI(4,5)P2 or PIP2) is degraded into diacylglycerol and inositol(1,4,5)triphosphate by phospholipase C to induce activation of protein kinase C and intracellular calcium mobilization, respectively [M. J. Berridge et al., Nature, 312, 315 (1984); Y. Nishizuka, Science, 225, 1365 (1984)].Phosphatidylinositol-3 kinase (“PI3K”) is an enzyme that phosphorylates the 3-position of the inositol ring of phosphatidylinositol [D. Whitman et al., Nature, 332, 664 (1988)]. Pluralities of PI3K subtypes exist. Three major subtypes of PI3Ks have now been identified on the basis of their in vitro substrate specificity, and these three are designated class I (a & b), class II, and class III [B. Vanhaesebroeck, Trend in Biol. Sci., 22, 267(1997)].The class Ia PI3K subtype has been most extensively investigated to date. Within the class Ia subtype there are three isoforms (α, β, & δ) that exist as hetero dimers of a catalytic 110-kDa subunit and regulatory subunits of 50-85 kDa. The regulatory subunits contain SH2 domains that bind to phosphorylated tyrosine residues within growth factor receptors or adaptor molecules and thereby localize PI3K to the inner cell membrane. At the inner cell membrane PI3K converts PIP2 to PIP3 (phosphatidylinositol-3,4,5-trisphosphate) that serves to localize the downstream effectors PDK1 and Akt to the inner cell ...

Подробнее
10-01-2019 дата публикации

COMPOSITION AND LIGHT EMITTING ELEMENT DEVICE USING THE SAME

Номер: US20190010134A1
Принадлежит:

A composition which is useful for production of a light emitting device excellent in light emission efficiency is provided. In particular, provided is a composition containing a compound represented by formula (1) and a phosphorescent compound, wherein Rand Reach independently represent a substituent, nrepresents an integer of 1 to 14, and Arrepresents an arylene group or a divalent heterocyclic group, and at least one of one or more groups Aris a group represented by the formula (1-A), wherein the variable groups Rto R, R, and Rare as defined in the specification. 2. The composition according to claim 1 , wherein one of Rand Ris a connecting bond claim 1 , and one of Rand Ris a connecting bond.3. The composition according to claim 1 , wherein Ris an alkyl group optionally having a substituent or a cycloalkyl group optionally having a substituent.4. The composition according to claim 1 , wherein Ris an aryl group optionally having a substituent.9. The composition according to claim 1 , wherein all of ngroups Arare groups represented by the formula (1-A).12. The composition according to claim 1 , further comprising at least one material selected from the group consisting of a hole transporting material claim 1 , a hole injection material claim 1 , an electron transporting material claim 1 , an electron injection material claim 1 , a light emitting material and an antioxidant.13. The composition according to claim 1 , further comprising a solvent.14. A light emitting device comprising the composition according to . The present invention relates to a composition and a light emitting device using the same.Light emitting devices such as an organic electroluminescent device can be suitably used for applications of display and illumination. As the light emitting material used in a light emitting layer of a light emitting device, for example, a composition comprising a fluorene compound 1 represented by the following formula and Ir (ppy)represented by the following formula ...

Подробнее
09-01-2020 дата публикации

Compound, And Organic Electronic Element Comprising Same

Номер: US20200010433A1
Принадлежит: LG Chem Ltd

The present specification relates to a compound of Chemical Formula 1 and an organic electronic device comprising the same.

Подробнее
14-01-2016 дата публикации

ORGANIC COMPOUND AND ORGANIC LIGHT EMITTING DIODE DEVICE INCLUDING THE SAME

Номер: US20160013420A1
Автор: JUNG Ji Yun
Принадлежит:

An organic compound is represented by Formula 1. 5. The organic light emitting diode device as claimed in claim 4 , whereinthe organic layer includes an electron transport layer, andthe organic compound represented by Formula 1 is included in the electron transport layer. Korean Patent Application No. 10-2014-0086973 filed on Jul. 10, 2014, in the Korean Intellectual Property Office, and entitled: “Organic Compound and Organic Light Emitting Diode Device Including the Same,” is incorporated by reference herein in its entirety.1. FieldEmbodiments relate to an organic compound and an organic light emitting diode device including the same.2. Description of the Related ArtRecent trends toward lightweight and thin personal computers and televisions sets also require lightweight and thin display devices, and flat panel displays satisfying such requirements are being substituted for conventional cathode ray tubes (CRTs.)However, since the LCD is a passive display device, an additional back-light as a light source is needed, and the LCD has various problems such as a slow response time and a narrow viewing angle. In this connection, an organic light emitting diode (OLED) display has recently been spotlighted as a display device that has merits such as a wide viewing angle, outstanding contrast, and a fast response time. In the organic light emitting diode device, electrons injected from one electrode and holes injected from another electrode are combined with each other in an emission layer, thereby generating excitons, and energy is outputted from the excitons to thereby emit light.Embodiments are directed to an organic compound represented by Formula 1:Wherein, Formula 1,Xand Xare CRor N,Rto Rare independently hydrogen, deuterium, a halogen, a C1 to C40 alkyl group, a C5 to C40 aryl group, a C5 to C40 heteroaryl group, a C5 to C40 aryloxy group, a C1 to C40 alkyloxy group, a C5 to C40 arylamino group, a C5 to C40 diarylamino group, a C6 to C40 arylalkyl group, a C3 to C40 ...

Подробнее
11-01-2018 дата публикации

Organic electroluminescent element

Номер: US20180013072A1
Принадлежит: Doosan Corp

The present invention provides an organic electroluminescent element which comprises: an anode; a cathode; and an organic layer interposed between the anode and the cathodes, wherein the organic layer comprises one or more types of layer from the group consisting of a hole-injection layer, hole-transport layer, light-emitting layer, lifetime enhancement layer, electron-transport layer, and electron-injection layer.

Подробнее
10-01-2019 дата публикации

HETEROCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THE SAME

Номер: US20190013480A1
Автор: Itoi Hiroaki
Принадлежит:

A heterocyclic compound represented by Formula 1 and an organic electroluminescence device including the same in an emission layer. 4. The heterocyclic compound of claim 3 , wherein a total number of N in Wto Wis 0 or 1.5. The heterocyclic compound of claim 1 , wherein L is a substituted or unsubstituted phenylene group.6. The heterocyclic compound of claim 1 , wherein at least one of R claim 1 , R claim 1 , R claim 1 , and Ris a substituted or unsubstituted phenyl group claim 1 , or a substituted or unsubstituted carbazole group.8. The heterocyclic compound of claim 1 , wherein a+b+d+e is 0 claim 1 , 1 or 2.11. The organic electroluminescence device of claim 10 , wherein the heterocyclic compound represented by Formula 1 is to emit blue light having a wavelength of less than about 470 nm.12. The organic electroluminescence device of claim 10 , wherein the heterocyclic compound represented by Formula 1 is to emit thermally activated delayed fluorescence.15. The organic electroluminescence device of claim 14 , wherein a total number of N in Wto Wis 0 or 1.16. The organic electroluminescence device of claim 10 , wherein Lisa substituted or unsubstituted phenylene group.17. The organic electroluminescence device of claim 10 , wherein at least one of R claim 10 , R claim 10 , R claim 10 , and Ris a substituted or unsubstituted phenyl group claim 10 , or a substituted or unsubstituted carbazole group.19. The organic electroluminescence device of claim 10 , wherein a+b+d+e is 0 claim 10 , 1 or 2. This application claims priority to and the benefit of Korean Patent Application No. 10-2017-0085060, filed in the Korean Intellectual Property Office on Jul. 4, 2017, the entire content of which is incorporated herein by reference.The present disclosure herein relates to a heterocyclic compound and an organic electroluminescence device including the same.The development of an organic electroluminescence display as an image display device is being actively conducted. The organic ...

Подробнее
14-01-2021 дата публикации

Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device

Номер: US20210013421A1

Provided is a novel heterocyclic compound, a novel heterocyclic compound that can be used in a light-emitting element, or a highly reliable light-emitting device, electronic device, and lighting device in each of which the light-emitting element using the novel heterocyclic compound is used. One embodiment of the present invention is a heterocyclic compound represented by General Formula (G1). 1. A light-emitting element comprising:a pair of electrodes;an electroluminescent layer between the pair of electrodes;a light-emitting layer in the electroluminescent layer;a first layer on the light-emitting layer; anda second layer on the first layer,wherein the light-emitting layer comprises a phosphorescent substance, and 'wherein the heterocyclic compound has an aryl group bonding to a triazine skeleton and the triazine skeleton bonding to a fluorene skeleton through an arylene group.', 'wherein the first layer comprises a heterocyclic compound,'}2. The light-emitting element according to claim 1 , wherein the fluorene skeleton is a substituted or unsubstituted 2-fluorenyl group.5. The light-emitting element according to claim 1 , wherein the aryl group has 6 to 13 carbon atoms.6. The light-emitting element according to claim 5 , wherein the aryl group is a phenyl group.7. The light-emitting element according to claim 1 , wherein the arylene group is a substituted or unsubstituted arylene group having 6 to 18 carbon atoms.8. The light-emitting element according to claim 7 , wherein the arylene group is a biphenylene group.9. The light-emitting element according to claim 1 , wherein the second layer comprises a substance having an electron-transport property.10. A light-emitting device comprising the light-emitting element according to claim 1 , comprising at least one of a transistor and a substrate.11. An electronic device comprising the light-emitting device according to claim 10 , comprising at least one of a microphone claim 10 , a camera claim 10 , an operation ...

Подробнее
14-01-2021 дата публикации

COMPOSITION FOR ORGANIC OPTOELECTRIC DEVICE AND ORGANIC OPTOELECTRIC DEVICE AND DISPLAY DEVICE

Номер: US20210013426A1
Принадлежит:

Disclosed are a composition for an organic optoelectric device including at least one of a first host compound represented by a combination of Chemical Formula 1 and Chemical Formula 2, and at least one of a second host compound represented by Chemical Formula 3, an organic optoelectric device including the same, and a display device. Details of Chemical Formulae 1 to 3 are the same as defined in the specification. 5. The composition for an organic optoelectric device of claim 1 ,{'sup': 1', '4, 'wherein Rand Rare independently hydrogen, deuterium, a substituted or unsubstituted phenyl group, a substituted or unsubstituted biphenyl group, or a substituted or unsubstituted terphenyl group, and'}{'sup': 2', '3, 'Rand Rare independently a substituted or unsubstituted phenyl group, a substituted or unsubstituted biphenyl group, a substituted or unsubstituted terphenyl group or a substituted or unsubstituted fluorenyl group.'}12. The composition for an organic optoelectric device of claim 1 , wherein the composition further includes a phosphorescent dopant.13. An organic optoelectric device comprisingan anode and a cathode facing each other, andat least one organic layer between the anode and the cathode,{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'wherein the organic layer includes the composition for an organic optoelectric device of .'}14. The organic optoelectric device of claim 13 , wherein the organic layer includes an emission layer claim 13 , andthe emission layer includes the composition for an organic optoelectric device.15. A display device comprising the organic optoelectric device of . This is a continuation application based on pending application Ser. No. 15/419,082, filed Jan. 30, 2017, the entire contents of which is hereby incorporated by reference.Korean Patent Application No. 10-2016-0048868, filed on Apr. 21, 2016, in the Korean Intellectual Property Office, and entitled: “Composition for organic optoelectric device and organic optoelectric ...

Подробнее
19-01-2017 дата публикации

HIGH-PRESSURE REACTOR FOR THE SYNTHESIS OF MELAMINE

Номер: US20170015636A1
Автор: Rizzi Enrico
Принадлежит: Casale SA

Reactor for the synthesis of melamine from urea, in accordance with the high-pressure non-catalytic process, comprising: a vertical reactor body (), at least one inlet () for the urea melt, a set of heating elements (), and a central duct (), said set of heating elements () being arranged inside said central duct. 1. A reactor for the synthesis of melamine from urea , according to the high-pressure non-catalytic process , comprising:a vertical reactor body, at least one inlet for the urea melt, a set of heating elements, and a central duct, wherein:said central duct delimits an inner reaction zone inside said duct, and a peripheral reaction zone around said duct, and said set of heating elements is arranged in the inner reaction zone inside said central duct.2. The reactor according to claim 1 , characterized by comprising no heating element inside said peripheral reaction zone.3. The reactor according to claim 1 , wherein said inlet for the urea melt is connected to a distributor configured to introduce urea into said peripheral reaction zone.4. The reactor according to claim 3 , said distributor being extended around the central duct and comprising urea delivery means which are arranged to introduce urea in a substantially uniform manner and with axial symmetry into said peripheral reaction zone.5. The reactor according to claim 4 , wherein said distributor has a substantially toroidal form.6. The reactor according to claim 1 , wherein a lower end of said central duct is distanced from a base of the set of heating elements claim 1 , thus defining a liquid recirculation passage between the inner reaction zone and the surrounding peripheral reaction zone.7. The reactor according to claim 1 , wherein said central duct extends claim 1 , inside the reactor claim 1 , up to a height lower than the height of the heating elements.8. The reactor according to claim 1 , wherein said central duct is delimited by a substantially cylindrical shell.9. The reactor according to ...

Подробнее
21-01-2016 дата публикации

Process for preparing tdi isocyanurate

Номер: US20160016917A1

The present invention relates to a method for preparing TDI (toluene diisocyanate) isocyanurate by using TDI, monohydric alcohol, solvent, antioxidant, catalyst and termination agent as the raw materials. The properties of the isocyanurate are improved by the process comprising the modification by monohydric alcohol and addition of the catalyst and solvent in several stages at an appropriate temperature. By adding the catalyst and solvent in batches at the condition of controlling both NCO % and the viscosity in the preparation process, and adjusting the solid content at each step, the resulting TDI isocyanurate has low content of free TDI, high xylene tolerance, small product color number, and high performance stability, which makes the product obtained by the isocyanurate have good application properties such as the drying, polishing and extinction properties of coating film, and such isocyanurate has good compatibility with other components.

Подробнее
15-01-2015 дата публикации

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Номер: US20150018328A1
Принадлежит: AGIOS PHARMACEUTICALS, INC

Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein. 3. The compound of claim 2 , wherein{'sup': 1', '3', '4', '6', '1', '3', '4', '6, 'sub': 1', '4', '1', '4', '1', '4', '2', '1', '4', '1', '4', '1', '4', '2, 'R, R, R, and Rare each independently selected from hydrogen, C-Calkyl, C-Chaloalkyl, —O—C-Calkyl, and CN, wherein each said alkyl moiety of R, R, R, and Rare each independently optionally substituted with —OH, —NH, —CN, —O—C-Calkyl, —NH(C-Calkyl), or —N(C-Calkyl); and'}{'sup': 2', '5', '6, 'sub': 1', '6', '1', '6', '2', '1', '6', '2', '2', '6', '1', '6', '1', '6', '0', '6', '1', '6', '0', '6', '1', '6, 'Rand Rare each independently selected from: —(C-Calkyl), —(C-Calkyl)-C(O)—NH, —(C-Calkyl)-COH, —(C-Calkenyl or alkynyl), —(C-Calkylene)-O—(C-Calkyl), —(C-Calkylene)-C(O)N(R)—(C-Calkyl), and —(C-Calkylene)-C(O)—(C-Calkyl), wherein{'sup': 2', '5, 'sub': 1', '4', '2, 'any alkyl or alkylene moiety present in Rand Ris optionally substituted with one or more —OH, —O(C-Calkyl), —COH, or halo; and'}{'sup': 2', '5, 'sub': 2', '3', '2', '2', '3', '3', '2, 'any terminal methyl moiety present in Rand Ris optionally replaced with —CHOH, CF, —CHF, —CHCl, C(O)CH, C(O)CF, CN, or COH;'}{'sup': 1', '3, 'Rand Rare optionally taken together with the carbon atom to which they are attached to form C(═O); or'}{'sup': 4', '6, 'Rand Rare optionally taken together with the carbon atom to which they are attached to form C(═O); or'}{'sup': 1', '2, 'Rand Rare optionally taken together to form an optionally substituted carbocyclyl; or'}{'sup': 4', '5', '7', '4', '5', '6', '8', '1', '2', '3, 'Rand Rare optionally taken together to form an optionally substituted carbocyclyl, wherein, when A is an optionally substituted phenyl, 2-pyrrolyl, or 1-imidazolyl, then N(R)C(R)(R)(R) is not the same as N(R)C(R)(R)(R), and the compound is not 2-(1,2-dibromoethyl)-4-phenyl-6-(1,1,2,2,3,3,4,4,5 ...

Подробнее
15-01-2015 дата публикации

ANTI-INFECTIVE COMPOUNDS

Номер: US20150018543A1
Принадлежит:

The present invention relates to 4H-pyrido[1,2-a]pyrimidin-4-one compounds and their use in the treatment of bacterial infections, in particular Tuberculosis. 1. A screening method comprising the steps of:{'i': 'M. tuberculosis', '(a) batch infection of host cells with fluorescently labeled mycobacteria;'}(b) removing free unbound mycobacteria;(c) adding compounds that are to be tested to a multi-well plate;{'i': 'M. tuberculosis', '(d) seeding said host cells infected with fluorescently labeled mycobacteria into said multi-well plate containing said compounds;'}{'i': 'M. tuberculosis', '(e) incubating said multi-well plate containing host cells infected with fluorescently labeled mycobacteria and said compounds;'}(f) fluorescently labeling said host cells; and(g) analyzing said multi-well plate using automated confocal microscopy.2M. tuberculosis. The method of claim 1 , wherein the screening method searches for compounds that interfere with the multiplication of within said host cells.3. The method of claim 1 , wherein the host cells are macrophages.4. The method of claim 3 , wherein the macrophages are live macrophages.5. The method of claim 1 , wherein the automated confocal fluorescence microscopy measures intracellular mycobacterial growth.6. The method of claim 1 , wherein step (g) comprises determining for each compounda total host cell number,a percentage of infected host cells; and/ora percent inhibition of infection.7. The method of claim 6 , wherein the host cells are macrophages.8. The method of claim 6 , wherein step (g) further comprises analyzing the total host cell number to determine if it is high or low; and wherein{'i': 'M. tuberculosis', '(i) a low total cell number is indicative for the compound toxicity and/or of the unrestricted growth of inside macrophages;'}and/or(ii) a high (total) cell number is indicative that the compound is not toxic and prevents mycobacterial growth.9. The method of claim 1 , further comprising the step of using ...

Подробнее
15-01-2015 дата публикации

Multifunctional sulfur-containing polymers, compositions thereof and methods of use

Номер: US20150018550A1
Принадлежит: PRC Desoto International Inc

Disclosed are multifunctional sulfur-containing polymers that are the reaction products of a sulfur-containing diol, a polyol containing at least three hydroxyl groups per polyol molecule, and an aldehyde, a ketone, or a combination thereof. Sealant compositions comprising the multifunctional sulfur-containing polymers are also disclosed.

Подробнее
16-01-2020 дата публикации

Hydantoin containing deoxyuridine triphosphatase inhibitors

Номер: US20200017481A1
Автор: Mark Spyvee
Принадлежит: Cv6 Therapeutics NI Ltd

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Подробнее
16-01-2020 дата публикации

ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES

Номер: US20200017508A1
Принадлежит: UNIVERSAL DISPLAY CORPORATION

A compound having a structure of Formula I, 2. The compound of claim 1 , wherein at least one R comprises at least one donor group selected from the group consisting of carbazole claim 1 , diphenylamino claim 1 , phenoxazine claim 1 , phenothiazine claim 1 , dibenzoazasiline claim 1 , pyrrolidine claim 1 , piperidine claim 1 , phenoxide claim 1 , and methoxide.3. The compound of claim 1 , wherein at least one R comprises at least one acceptor group selected from the group consisting of cyano claim 1 , pyrazole claim 1 , imidazole claim 1 , triazole claim 1 , pyridine claim 1 , pyrimidine claim 1 , triazine claim 1 , aza-carbazole claim 1 , aza-dibenzofuran claim 1 , and aza-dibenzothiophene group.4. The compound of claim 1 , wherein each one of Zthrough Zis CR.5. The compound of claim 1 , wherein at least one of Zthrough Zis N.7. The compound of claim 1 , wherein at least two Rs comprise donor substituents claim 1 , and one R comprises an acceptor substituent; or at least two Rs comprise acceptor substituents claim 1 , and one R comprises a donor substituent.10. The OLED of claim 9 , wherein the organic layer is an emissive layer and the compound is a host.11. The OLED of claim 9 , wherein the organic layer is a blocking layer and the compound is a blocking material in the organic layer claim 9 , or organic layer is a transporting layer and the compound is a transporting material in the organic layer.12. The OLED of claim 9 , wherein the organic layer is an emissive layer and the compound is an emitter.13. The OLED of claim 12 , wherein the OLED emits a luminescent radiation at room temperature when a voltage is applied across the first organic light emitting device; wherein the luminescent radiation comprises a delayed fluorescent process.14. The OLED of claim 13 , wherein the organic layer further comprises a sensitizer; andwherein the sensitizer is a phosphorescent emitting material.15. The OLED of claim 9 , wherein the organic layer further comprises a ...

Подробнее
16-01-2020 дата публикации

High Thermal Stability Melamine Octamolybdate and Use Thereof as a Smoke Suppressant in Polymer Compositions

Номер: US20200017659A1
Принадлежит:

Processes for producing melamine octamolybdates having high thermal stability include a step of reacting molybdenum trioxide and melamine in an acidic aqueous system at a pH of less than or equal to about 4 to form a slurry of the melamine octamolybdate. The resulting melamine octamolybdate can be characterized by a decomposition onset temperature (or a temperature at a weight loss of 1%, or a temperature at a weight loss of 2%) on a thermogravimetric analysis curve of greater than 300° C., and is useful in polymer compositions as a smoke suppressant. 111-. (canceled)12. Melamine octamolybdate characterized by:a temperature at a weight loss of 1% on a thermogravimetric analysis curve in a range from about 300° C. to about 500° C.; anda temperature at a weight loss of 2% on a thermogravimetric analysis curve in a range from about 300° C. to about 500° C.13. The melamine octamolybdate of claim 12 , wherein the melamine octamolybdate is further characterized by:a temperature at a weight loss of 1% on a thermogravimetric analysis curve in a range from about 330° C. to about 400° C.; and/ora temperature at a weight loss of 2% on a thermogravimetric analysis curve in a range from about 325° C. to about 475° C.14. A polymer composition comprising:(a) a polymer; and(b) a melamine octamolybdate characterized by:a temperature at a weight loss of 1% on a thermogravimetric analysis curve in a range from about 300° C. to about 500° C.; and/ora temperature at a weight loss of 2% on a thermogravimetric analysis curve in a range from about 300° C. to about 500° C.15. The polymer composition of claim 14 , wherein the polymer comprises a thermoplastic polymer.16. The polymer composition of claim 14 , wherein the polymer comprises a rigid PVC or a flexible PVC.17. The polymer composition of claim 14 , wherein a weight ratio of polymer:melamine octamolybdate is in a range from about 100:1 to about 100:40.18. The polymer composition of claim 14 , wherein the polymer composition further ...

Подробнее
19-01-2017 дата публикации

HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME

Номер: US20170018718A1
Принадлежит: LG CHEM, LTD.

The present specification provides a hetero-cyclic compound and an organic light emitting device comprising the same. 5. The compound of claim 1 , wherein L is naphthylene; phenanthrylene; or fluorenylene substituted with an alkyl group.6. The compound of claim 1 , wherein Ar1 and Ar2 are the same as each other claim 1 , and a phenyl group; a biphenyl group; a naphthyl group; or a phenanthryl group.7. The compound of claim 1 , wherein R1 and R2 are the same as or different from each other claim 1 , and each independently an alkyl group; or an aryl group claim 1 , which is unsubstituted or substituted with one or more substituents selected from the group consisting of deuterium claim 1 , and an alkyl group claim 1 , or combine with each other to form a ring.8. The compound of claim 1 , wherein R3 and R4 are the same as or different from each other claim 1 , and each independently hydrogen; deuterium; an alkyl group; an alkoxy group; or an aryl group.11. An organic light emitting device claim 1 , comprising:a first electrode;a second electrode provided to face the first electrode; andone or more organic material layers provided between the first electrode and the second electrode,{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'wherein one or more layers of the organic material layers comprise the compound of .'}12. The organic light emitting device of claim 11 , wherein the organic material layer comprising the compound is a hole injection layer claim 11 , a hole transporting layer claim 11 , or a layer which simultaneously injects and transports holes.13. The organic light emitting device of claim 11 , wherein the organic material layer comprising the compound is an electron injection layer claim 11 , an electron transporting layer claim 11 , or a layer which simultaneously injects and transports electrons.14. The organic light emitting device of claim 11 , wherein the organic material layer comprising the compound is a light emitting layer. The present ...

Подробнее
17-01-2019 дата публикации

COMPOSITION FOR FORMING ORGANIC FILM, DISPLAY DEVICE USING THE COMPOSITION, AND METHOD OF MANUFACTURING THE DISPLAY DEVICE

Номер: US20190019958A1
Принадлежит:

A composition for forming organic film, a display device utilizing the composition, and a method of manufacturing the display device are provided. The composition for forming an organic film includes a solvent; and a compound of Formula 1: 13. The display device of claim 12 , wherein the display comprisesa first pixel configured to display a first color,a second pixel adjacent to the first pixel and configured to display a second color having a longer peak wavelength than the first color, anda third pixel adjacent to the first pixel and configured to display the first color,wherein the first organic layer in the first pixel is physically spaced apart from the first organic layer in the third pixel.16. The display device of claim 15 , whereinthe organic layers further comprise a fourth organic layer between the second organic layer and the cathode electrode and between the third organic layer and the cathode electrode, andthe fourth organic layer in the first pixel is physically formed in one integral body with the fourth organic layer in the third pixel.18. The method of claim 17 , wherein the forming of the organic layer patterns comprises:placing a mask having openings over the coating layer,partially exposing and curing the coating layer by applying light, anddeveloping the cured coating layer utilizing a developer.19. The method of claim 18 , further comprising claim 18 , before the forming of the coating layer:forming an electrode layer on the base; andforming a bank having openings to expose a surface of the electrode layer.20. The method of claim 18 , further comprising claim 18 , after the forming the organic layer patterns:forming a bank having openings to expose the surfaces of the organic layer patterns. This application claims priority to and the benefit of Korean Patent Application No. 10-2017-0088354, filed in the Korean Intellectual Property Office on Jul. 12, 2017, the disclosure of which is incorporated herein by reference in its entirety.The ...

Подробнее
17-01-2019 дата публикации

MODIFIED IONIC LIQUIDS CONTAINING TRIAZINE

Номер: US20190020061A1
Принадлежит:

The present disclosure is directed to a triazine-modified ionic liquid compound, the synthesis thereof and an electrochemical cell electrolyte containing the triazine-modified ionic liquid compound. 2. The compound of claim 1 , wherein the anion comprises a halide claim 1 , aluminate claim 1 , arsenide claim 1 , cyanide claim 1 , thiocyanate claim 1 , nitrite claim 1 , benzoate claim 1 , chlorate claim 1 , chlorite claim 1 , chromate claim 1 , sulfate claim 1 , sulfite claim 1 , silicate claim 1 , thiosulfate claim 1 , oxalate claim 1 , acetate claim 1 , formate claim 1 , hydroxide claim 1 , nitrate claim 1 , phosphate claim 1 , imide claim 1 , or borate.3. An electrical energy storage device electrolyte comprising:a) an aprotic organic solvent system;b) an alkali metal salt;c) an additive; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'd) an ionic liquid compound according to .'}4. The electrolyte of claim 3 , wherein the anion anion of either or both of the alkali metal salt and ionic liquid comprises a halide claim 3 , aluminate claim 3 , arsenide claim 3 , cyanide claim 3 , thiocyanate claim 3 , nitrite claim 3 , benzoate claim 3 , chlorate claim 3 , chlorite claim 3 , chromate claim 3 , sulfate claim 3 , sulfite claim 3 , silicate claim 3 , thiosulfate claim 3 , oxalate claim 3 , acetate claim 3 , formate claim 3 , hydroxide claim 3 , nitrate claim 3 , phosphate claim 3 , imide claim 3 , or borate.5. The electrolyte of claim 3 , wherein the aprotic organic solvent comprises an open-chain or cyclic carbonate claim 3 , carboxylic acid ester claim 3 , nitrite claim 3 , ether claim 3 , sulfone claim 3 , ketone claim 3 , lactone claim 3 , dioxolane claim 3 , glyme claim 3 , crown ether claim 3 , siloxane claim 3 , phosphoric acid ester claim 3 , phosphate claim 3 , phosphite claim 3 , mono- or polyphosphazene or mixtures thereof.6. The electrolyte of claim 3 , wherein the cation of the alkali metal salt comprises lithium claim 3 , sodium claim 3 , aluminum or ...

Подробнее
17-01-2019 дата публикации

Modified Triazine Functional Compounds

Номер: US20190020062A1
Принадлежит: NOHMs Technologies Inc

The present invention is directed towards phosphorous containing flame retarding materials including a triazine moiety and an electrolyte for electrochemical cells containing the same.

Подробнее
21-01-2021 дата публикации

ORGANIC LIGHT-EMITTING DEVICE

Номер: US20210020842A1
Принадлежит:

Provided is an organic light-emitting device comprising: a first electrode; a second electrode provided to face the first electrode; and a first organic material layer and a second organic material layer provided between the first electrode and the second electrode, in which the first organic material layer includes a compound of Formula 1, and the second organic material layer includes a compound of Formula 2. 4. The organic light emitting device of claim 1 , wherein the first organic material layer comprises a light emitting layer claim 1 , and the light emitting layer comprises the compound of Formula 1.5. The organic light emitting device of claim 1 , wherein the second organic material layer comprises a hole blocking layer claim 1 , an electron transport layer claim 1 , an electron injection layer claim 1 , or an electron injection and transport layer claim 1 , and the hole blocking layer claim 1 , the electron transport layer claim 1 , the electron injection layer claim 1 , or the electron injection and transport layer comprises the compound of Formula 2.6. The organic light emitting device of claim 1 , wherein the second organic material layer is provided to be brought into contact with the first organic material layer.7. The organic light emitting device of claim 4 , wherein the compound of Formula 1 is a host of the light emitting layer. This application is a National Stage Application of International Application No. PCT/KR2019/006863 filed on Jun. 7, 2019, which claims priority to and the benefit of Korean Patent Application No. 10-2018-0066125 filed in the Korean Intellectual Property Office on Jun. 8, 2018, the entire contents of which are incorporated herein by reference.The present application relates to an organic light emitting device.In general, an organic light emitting phenomenon refers to a phenomenon in which electric energy is converted into light energy by using an organic material. An organic light emitting device using the organic light ...

Подробнее
21-01-2021 дата публикации

POLYCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME

Номер: US20210020848A1
Принадлежит:

Provided is a compound of Chemical Formula 1: 4. The compound of claim 1 , wherein L1 and L2 are the same as or different from each other claim 1 , and each independently is selected from among a direct bond claim 1 , phenylene claim 1 , biphenylylene claim 1 , terphenylylene claim 1 , quaterphenylylene claim 1 , naphthylene claim 1 , anthracenylene claim 1 , fluorenylene unsubstituted or substituted with alkyl or aryl claim 1 , phenanthrenylene claim 1 , pyrenylene and triphenylylene.5. The compound of claim 1 , wherein:R1 and R2 are all an alkyl group, orR1 and R2 are all an aryl group, orR1 is an alkyl group and R2 is an aryl group.7. An organic light emitting device comprising:a first electrode;a second electrode provided opposite to the first electrode; andone, two or more organic material layers provided between the first electrode and the second electrode,{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'wherein one or more layers of the organic material layers include the compound of .'}8. The organic light emitting device of claim 7 , wherein the organic material layer includes a hole blocking layer claim 7 , an electron transfer layer claim 7 , an electron injection layer claim 7 , or an electron injection and transfer layer claim 7 , and the hole blocking layer claim 7 , the electron transfer layer claim 7 , the electron injection layer claim 7 , or the electron injection and transfer layer includes the compound. This application is a National Stage Application of International Application No. PCT/KR2019/002602 filed on Mar. 6, 2019, which claims priority to and the benefits of Korean Patent Application No. 10-2018-0026436, filed with the Korean Intellectual Property Office on Mar. 6, 2018, the entire contents of which are incorporated herein by reference.The present specification relates to a polycyclic compound, and an organic light emitting device including the same.An organic light emission phenomenon generally refers to a phenomenon converting ...

Подробнее
21-01-2021 дата публикации

NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY

Номер: US20210020990A1

Provided is a non-aqueous electrolyte secondary battery comprising: a positive electrode including a positive electrode active material; a negative electrode; and a non-aqueous electrolyte, wherein the positive electrode active material has a composite oxide containing Ni and Li, the proportion of Ni being at least 33 mol % with respect to the total number of moles of metal elements other than Li, and the non-aqueous electrolyte contains: a non-aqueous solvent containing a fluorine-containing cyclic carbonate; an isocyanurate derivative such as triallyl isocyanurate; and a cyclic carboxylic anhydride such as a succinic anhydride. 2. The non-aqueous electrolyte secondary battery according to claim 1 , whereinthe composite oxide has a proportion of Ni of 75 mol % or more based on the total number of moles of the metal elements except for Li.3. The non-aqueous electrolyte secondary battery according to claim 1 , whereina content of the fluorine-containing cyclic carbonate is 0.1% by volume or more and 30% by volume or less based on the total volume of the non-aqueous solvent.4. The non-aqueous electrolyte secondary battery according to claim 1 , whereina content of the cyclic carboxylic anhydride is 0.1% by mass or more and 1.5% by mass or less based on the total mass of the non-aqueous electrolyte.5. The non-aqueous electrolyte secondary battery according to claim 1 , whereina content of the isocyanuric acid derivative is 0.1% by mass or more and 1.5% by mass or less based on the total mass of the non-aqueous electrolyte.6. The non-aqueous electrolyte secondary battery according to claim 1 , whereinthe cyclic carboxylic anhydride includes at least one of the group consisting of succinic anhydride and glutaric anhydride.7. The non-aqueous electrolyte secondary battery according to claim 1 , whereinthe isocyanuric acid derivative includes triallyl isocyanurate.8. The non-aqueous electrolyte secondary battery according to claim 1 , whereinthe composite oxide includes at ...

Подробнее
21-01-2021 дата публикации

NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY

Номер: US20210020991A1
Автор: NAKAZAWA Eiji
Принадлежит: MITSUBISHI CHEMICAL CORPORATION

Provided is a nonaqueous electrolyte battery in which not only the generation of a gas during high-temperature storage but also an increase in the battery resistance are inhibited. Also provided is a nonaqueous electrolyte solution containing: a compound represented by the following Formula (A); a cyclic carbonate having an unsaturated carbon-carbon bond; and at least one compound selected from the group consisting of compounds represented by the following Formula (B) or (C). In this nonaqueous electrolyte solution, the content of the cyclic carbonate having an unsaturated carbon-carbon bond with respect to a total amount of the nonaqueous electrolyte solution is in a specific range, and the content of the at least one compound selected from the group consisting of compounds represented by Formula (B) or (C) is in a specific range. 2. The nonaqueous electrolyte solution according to claim 1 , wherein claim 1 , in Formula (B) claim 1 , the hydrocarbon group having an unsaturated carbon-carbon bond is an allyl group or a methallyl group.3. The nonaqueous electrolyte solution according to claim 1 , further comprising a fluorine atom-containing cyclic carbonate.4. The nonaqueous electrolyte solution according to claim 3 , wherein the content of the fluorine atom-containing cyclic carbonate is 0.01% by mass or higher and 5% by mass or less with respect to a total amount of the nonaqueous electrolyte solution.5. The nonaqueous electrolyte solution according to claim 1 , further comprising at least one salt selected from the group consisting of a fluorinated salt and an oxalate salt.6. The nonaqueous electrolyte solution according to claim 5 , wherein the content of the fluorinated salt and/or the oxalate salt is 0.01% by mass or higher and 5% by mass or less with respect to a total amount of the nonaqueous electrolyte solution.7. A nonaqueous electrolyte battery claim 5 , comprising:a positive electrode and a negative electrode, which are capable of absorbing and ...

Подробнее
26-01-2017 дата публикации

DIAMINOTRIAZINE DERIVATIVES AS HERBICIDES

Номер: US20170022170A1
Принадлежит:

The present invention relates to diaminotriazine compounds of the formula (I) and to their use as herbicides. The present invention also relates to agrochemical compositions for crop protection and to a method for controlling unwanted vegetation. 117-. (canceled)19. The compound of claim 18 , wherein Ris selected from the group consisting of C-C-haloalkoxy claim 18 , C-C-alkenyloxy claim 18 , C-C-haloalkenyloxy claim 18 , C-C-alkynyloxy claim 18 , C-C-haloalkynyloxy claim 18 , (C-C-alkoxy)-C-C-alkoxy claim 18 , C-C-cycloalkoxy claim 18 , C-C-halocycloalkoxy claim 18 , (C-C-cycloalkyl)-C-C-alkoxy and (C-C-halocycloalkyl)-C-C-alkoxy.20. The compound of claim 18 , wherein Ris C-C-cycloalkoxy claim 18 , C-C-alkenyloxy claim 18 , C-C-alkynyloxy or (C-C-cycloalkyl)-C-C-alkoxy.21. The compound of claim 18 , wherein Ris selected from the group consisting of halogen claim 18 , CN claim 18 , C-C-alkoxy claim 18 , C-C-haloalkoxy claim 18 , C-C-cycloalkoxy and C-C-halocycloalkoxy.23. The compound of claim 21 , wherein R claim 21 , Rand Rare selected from the group consisting of and hydrogen and fluorine.25. The compound of claim 18 , wherein Ris H claim 18 , CN claim 18 , C-C-alkyl claim 18 , (C-C-alkoxy)-C-C-alkyl claim 18 , C-C-alkoxy claim 18 , (C-C-alkyl)carbonyl claim 18 , (C-C-cycloalkyl)carbonyl or (C-C-alkyl)sulfonyl.26. The compound of claim 25 , wherein Ris H.27. The compound of claim 18 , wherein Ris H claim 18 , CN claim 18 , C-C-alkyl claim 18 , (C-C-alkoxy)-C-C-alkyl claim 18 , (C-C-alkyl)carbonyl claim 18 , (C-C-cycloalkyl)carbonyl or (C-C-alkyl)sulfonyl.28. The compound of claim 27 , wherein Ris H.29. The compound of claim 18 , wherein Ris selected from the group consisting of hydrogen claim 18 , fluorine claim 18 , chlorine claim 18 , C-C-alkyl and C-C-alkoxy.30. The compound of claim 18 , wherein Ris selected from the group consisting of hydrogen claim 18 , fluorine claim 18 , C-C-alkyl claim 18 , C-C-haloalkyl claim 18 , C-C-alkoxy and C-C-haloalkoxy.31. The ...

Подробнее
25-01-2018 дата публикации

N2-(3,4-DIMETHYLPHENYL)-6-((4-(P-TOLYL)PIPERAZIN-1-YL)METHYL)-1,3,5-TRIAZINE-2,4-DIAMINE

Номер: US20180022715A1
Принадлежит:

The compound N-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamineor a pharmaceutically acceptable salt of said compound. The compound is useful the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidaseactivity. A pharmaceutical composition comprising the compound. 24.-. (canceled)5. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt according to and optionally a pharmaceutically acceptable excipient.616.-. (canceled)17. A method of treatment of a condition or disorder selected from endocrine disorders claim 1 , cardiovascular disorders claim 1 , respiratory disorders claim 1 , metabolism disorders claim 1 , skin disorders claim 1 , bone disorders claim 1 , neuroinflammatory and/or neurodegenerative disorders claim 1 , kidney diseases claim 1 , reproduction disorders claim 1 , diseases affecting the eye and/or the lens and/or conditions affecting the inner ear claim 1 , inflammatory disorders claim 1 , liver diseases claim 1 , pain claim 1 , cancers claim 1 , allergic disorders claim 1 , traumatisms claim 1 , septic claim 1 , hemorrhagic and anaphylactic shock claim 1 , diseases or disorders of the gastrointestinal system claim 1 , abnormal angiogenesis and angiogenesis-dependent conditions claim 1 , lung infections claim 1 , acute lung injury claim 1 , pulmonary arterial hypertension claim 1 , obstructive lung disorders claim 1 , and fibrotic lung disease claim 1 , by administering the compound N-(3 claim 1 ,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1 claim 1 ,3 claim 1 ,5-triazine-2 claim 1 ,4-diamine claim 1 , or a pharmaceutically acceptable salt of said compound claim 1 , to a mammal in need of such treatment.18. The method of claim 17 , wherein the mammal is a human.19. The method of claim 17 , wherein the mammal is a non-human mammal.20. The method of claim 17 , wherein the non-human mammal is a dog or a cat.21. The ...

Подробнее
25-01-2018 дата публикации

ORGANIC ELECTROLUMINESCENT COMPOUNDS AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME

Номер: US20180022991A1
Принадлежит:

The present invention relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound according to the present invention can be comprised in a light-emitting layer or an electron buffer layer, and is effective to produce an organic electroluminescent device having low driving voltage, excellent current and power efficiencies, and significantly improved operational lifespan. 2. The organic electroluminescent compound according to claim 1 , wherein the substituents of the substituted (C1-C30)alkyl claim 1 , the substituted (C6-C30)aryl claim 1 , the substituted 3- to 30-membered heteroaryl claim 1 , the substituted (C3-C30)cycloalkyl claim 1 , the substituted (C1-C30)alkoxy claim 1 , the substituted tri(C1-C30)alkylsilyl claim 1 , the substituted di(C1-C30)alkyl(C6-C30)arylsilyl claim 1 , the substituted (C1-C30)alkyldi(C6-C30)arylsilyl claim 1 , the substituted tri(C6-C30)arylsilyl claim 1 , the substituted mono- or di-(C1-C30)alkylamino claim 1 , the substituted mono- or di-(C6-C30)arylamino claim 1 , the substituted (C1-C30)alkyl(C6-C30)arylamino claim 1 , and the substituted mono- or polycyclic claim 1 , (C3-C30) alicyclic or aromatic ring in Rto Reach independently are at least one selected from the group consisting of deuterium claim 1 , a halogen claim 1 , a cyano claim 1 , a carboxyl claim 1 , a nitro claim 1 , a hydroxyl claim 1 , a (C1-C30)alkyl claim 1 , a halo(C1-C30)alkyl claim 1 , a (C2-C30) alkenyl claim 1 , a (C2-C30) alkynyl claim 1 , a (C1-C30)alkoxy claim 1 , a (C1-C30)alkylthio claim 1 , a (C3-C30)cycloalkyl claim 1 , a (C3-C30)cycloalkenyl claim 1 , a 3- to 7-membered heterocycloalkyl claim 1 , a (C6-C30)aryloxy claim 1 , a (C6-C30)arylthio claim 1 , a 5- to 30-membered heteroaryl unsubstituted or substituted with a (C6-C30)aryl claim 1 , a (C6-C30)aryl unsubstituted or substituted with a 5- to 30-membered heteroaryl claim 1 , a tri(C1-C30)alkylsilyl claim 1 , ...

Подробнее